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Abstract
Parkinson's disease (PD) is an age-related degenerative disease of the brain, characterized by
motor, cognitive, and psychiatric symptoms. Neurologists and neuroscientists now understand
that several symptoms of the disease, including hallucinations and impulse control behaviors,
stem from the dopaminergic medications used to control the motor aspects of PD. Not all
patients experience these nonmotor symptoms and tools that can predict a priori which
patients are likely to have an adverse response to medication do not exist. This thesis begins to
fill this gap by elucidating the mechanisms underlying the adverse effects of dopaminergic
medications. Converging evidence from animals and humans shows that individual differences
in particular genes that affect the dopamine system may alter the response of PD patients to
dopaminergic medication. We examined the hypothesis that patients taking dopamine
replacement therapy who carry candidate alleles that increase dopamine signaling experience a
dopamine overdose, causing unwanted psychiatric symptoms.
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Preface
This thesis is comprised of six chapters. Chapter 1, the Introduction, frames the overarching
question addressed in the thesis: What are the mechanisms underlying the adverse effects of
dopaminergic medications used to ameliorate motor symptoms of Parkinson's disease (PD). To
tackle this question, I focus on two medication-induced side effects observed in PD: impulse
control behaviors and hallucinations. Chapters 2-4 probe three distinct dimensions of
impulsivity, response inhibition, delay of gratification, and reflection impulsivity. The focus of
chapter 5 is hallucinations. I present each chapter with its own introduction, methods, and
discussion. Chapter 6, the Conclusion, summarizes the major findings and discusses directions
for future research.
1 Introduction
Parkinson's disease (PD) is an age-related neurodegenerative disease commonly characterized
by resting tremor, rigidity, slowness of movement, and postural instability. These symptoms
progress relentlessly, eventually leaving most patients wheelchair bound and entirely
dependent on caregivers. PD occurs worldwide and affects all races and both sexes, but with a
slight predominance among males.1 Motor symptoms of the disease typically appear when
patients are in their early sixties, although up to 10% of those affected start experiencing
symptoms between the ages of 30 and 60.1,2 PD prevalence increases from roughly 0.3% in the
general population to 0.6% to 1% among people 65 to 69 years of age, and 1% to 3% among
people older than 70.3 It is the second most common neurodegenerative disease, after
Alzheimer's disease, and currently 40,000 to 70,000 new cases are diagnosed each year in the
United States alone.3 4 The number of individuals with PD is expected to double by the year
2030 as life expectancies increase and the global population shifts in age.s
James Parkinson was the first to describe the disorder in his 1817 paper, "An Essay on the
Shaking Palsy", 6 although a disease named "Kampavata", described in the ancient Ayurvedic
literature of India, compiled from 4500 B.C. to 1000 B.C., bears a striking resemblance to PD.7
Parkinson reported that the "senses and intellects" remain intact in PD, 6 but we now know that
the extrapyramidal symptoms are accompanied by a broad range of nonmotor symptoms.
Cognitive symptoms include visuospatial deficits and difficulty in tasks that require coordination
of action and thought to achieve a goal. 2,8 Psychiatric disorders consist of anxiety, dementia,
2,depression, impulse control behaviors, insomnia, and hallucinations. These nonmotor
aspects significantly reduce patients' quality of life, and typically do not respond to, or are
worsened by, medication used to treat the motor symptoms.2
1.1 Neuropathology of PD
The major neuropathologic feature of idiopathic PD is selective loss of dopaminergic neurons in
the midbrain. Dopaminergic degeneration in the early stages of PD is selective, targeting the
ventrolateral tier of the substantia nigra pars compacta (SNpc) followed by the dorsolateral tier
of SNpc. The ventral tegmental area (VTA) is relatively spared912 Patients who die with a
diagnosis of PD show a 60% to 85% loss of tyrosine hydroxylase immunoreactive neurons in the
SNpc, with 91% to 97% loss in the ventrolateral tier of SNpc and 40% to 50% loss in the
VTA. 9,13,14
SNpc and VTA are interconnected with the striatum in an inverse dorsal-ventral pattern.15 The
striatum-putamen and the caudate nucleus-is located in the forebrain under the frontal
lobes. It is the primary input node of the basal ganglia. Ventrolateral SNpc is interconnected
with the dorsal striatum (primarily putamen), while dorsolateral SNpc and VTA are
interconnected with the central (head of the caudate nucleus and rostral putamen) and ventral
regions of the striatum (nucleus accumbens, and rostral/ventral caudate nucleus, and
putamen), respectively. 5 ,16 Thus, the pattern of cell loss in the early stages of PD causes severe
dopamine depletion in the dorsal striatum, moderate depletion in the central striatum, while
relatively sparing dopaminergic function in the ventral striatum. 4'
Different sectors of the striatum are connected with specific regions of the cortex by
functionally distinct cortico-striatal loops.19-23 The motor loop connects motor, premotor, and
supplementary motor areas with the dorsal striatum. The associative loop, which is implicated
in attentional control and maintenance and manipulation of information to achieve a goal,
connects dorsolateral prefrontal cortex (PFC), pre-supplementary motor area (pre-SMA), and
posterior parietal cortex with the central striatum. The limbic loop, implicated in emotion,
motivation, and reward processing, connects orbital/medial regions of PFC, hippocampus,
amygdala, and the anterior cingulate cortex with the ventral striatum. Dopamine depletion in
the dorsal striatum alters the motor loop function, causing the motor symptoms of PD.
Protective or preventive treatments for PD do not exist. The gold standard for reducing the
motor symptoms is to increase dopaminergic transmission in the motor loop by giving patients
the dopamine precursor levodopa or dopamine agonists. Levodopa is taken up by
dopaminergic terminals and converted into dopamine by DOPA decarboxylase. Dopamine
agonists, such as pramipexole, ropinirole, and bromocriptine, directly stimulate dopamine
receptors. The resulting improvement in motor signs comes at a price. Use of levodopa or
dopamine agonists may cause psychiatric side effects, such as hallucinations and impulse
control behaviors, possibly due to over stimulation of the relatively preserved cortico-striatal
loops.24,2s
1.2 Psychiatric complications in PD
1.2.1 Impulse control behaviors
Impulsivity is "a predisposition toward rapid, unplanned reactions to internal or external stimuli
without regard to the negative consequences of these reactions to the impulsive individual or
to others". 26,27 Impulsive behaviors in PD may include pathologic gambling, binge eating,
hypersexuality, and excessive shopping.27-31 The Diagnostic and Statistical Manual of Mental
Disorders, 4 th edition, text revision (DSM-IV-TR; American Psychiatric Association 2000), lists the
criteria for impulse control disorders, but diagnostic criteria for excessive shopping and
hypersexuality are lacking.2'3 Point prevalence of at least one impulse control behavior
(pathologic gambling, binge eating, hypersexuality, or excessive shopping) is 6.9% in patients
taking levodopa without a dopamine agonist, and 17.1% in patients taking levodopa and
dopamine agonists.,33, Pathologic gambling is one of the more common side effects of
treatment with a prevalence of 6.4% in patients taking levodopa and dopamine agonists,
compared to a prevalence of 1% in the general population. 27,33,35
Manifestations of impulsivity typically result in irreversible personal, social, and financial
*36,37ruin. ' One study calculated that the financial loss averages more than $100,000 for patients
who pathologically gamble,36 constituting a devastating blow to families who are at retirement
age and must bear the additional burden of medical expenses.
Impulsivity in PD has been studied predominantly by clinical interviews or self-report
questionnaires, such as the Barratt Impulsiveness Scale (BIS-11) 38 and the Eysenck Personality
Questionnaire. 39 Although information gained from these questionnaires and interviews is
invaluable, it is hard to relate aspects of impulsivity measured by these methods to underlying
brain function because they are too nonspecific. Importantly, these questionnaires were not
developed for studying transient medication-induced impulsivity or patients with a movement
disorder.
Behavioral research on the neural and chemical underpinnings of impulsivity has focused on
three domains: response inhibition, the ability to inhibit a prepotent response; delay of
gratification, the ability to forgo small immediate rewards for larger delayed rewards; and
reflection impulsivity, the ability to collect and evaluate information before making a
decision.40' 4 1 The experiments described in Chapters 2-4 focus on each of these domains in
turn to clarify the underpinnings of medication-induced impulsivity in PD.
1.2.2 Hallucinations
According to DSM-IV-TR, a hallucination is "a sensory perception that has the compelling sense
of reality of a true perception but that occurs without external stimulation of the relevant
sensory organ". 4 2 Hallucinations in PD are predominantly visual, typically fully formed non-
threatening images of people and animals. Many patients with visual hallucinations also
experience auditory hallucinations.43 44 In addition, "minor" or "benign" hallucinationatory
experiences, such as a sense of presence of someone when no one is there, a sense of
movement, and illusions of inanimate objects appearing as living beings, are also common.43 4 s
About 30% of PD patients taking dopamine replacement therapy experience visual or auditory
hallucinations.43 4 s The prevalence of hallucinations increases to 40% to 75% when minor
hallucination are also considered.43 Once developed, hallucinations persist and progress, are
associated with an increased risk of developing dementia, and are a primary risk factor for
46-50nursing home placement and its associated high mortality rates.
The presence of formed and benign hallucinations in PD patients is typically assessed by self-
report questionnaires because patients generally retain insight into their hallucinations, at least
in the early stages of the disease.43 A positive response to a screening question is followed by a
structured interview to confirm the presence of major and minor hallucinations, and to assess
when hallucinations first started. Chapter 5 examines Hallucinations in PD.
1.3 Relation between psychiatric complications and medication use
Hallucinations and impulse control behaviors typically start, with variable latencies, after the
introduction of dopaminergic medications or after a dose increase. They often remit when
medication is decreased or discontinued.3 s43 44 All dopaminergic medications (levodopa,
dopamine agonists) can induce psychiatric side effects, but agonists are more likely to do so
than levodopa.33 ,3 s,44
While dopamine replacement therapy improves motor function in PD by increasing signaling in
the dopamine-depleted cortico-striatal motor loop, it can have beneficial and deleterious
effects on cognitive functions subserved by the associative and the limbic loops.2 4,51 ,5 2 Early
stage patients taking dopamine replacement therapy perform better than those who are off
medication in tasks that engage the associative loop, such as task switching, planning and
working memory.s3 They perform worse than unmediated patients in tasks that activate the
limbic loop, such as probabilistic reversal learning.24 The idea that dopamine replacement
therapy can have an opposing impact on functions that engage the associative and limbic loops,
respectively, is known as the dopamine overdose hypothesis. 24 Although this hypothesis
provides an explanation for the interaction between medication status and cognitive
performance at a group level, it cannot account for individual variability in cognitive
performance, nor is it able to predict which patients are likely to experience cognitive
deterioration while receiving dopamine replacement therapy. Our goal is to flesh out this
hypothesis by elucidating the mechanisms that give rise to medication-induced side effects in
PD.
Insights about the mechanisms by which dopaminergic medications cause side effects come
from three findings: First, not all patients taking dopamine replacement therapy develop the
side effects. Second, levodopa daily dose and levodopa-equivalent daily dose (LEDD) are similar
for patients who develop the side effects and those who do not.3 3,35 ,43,44 Third, although
dopamine agonists carry a higher risk for side effects, commonly prescribed dopamine agonists,
such as pramipexole, ropinirole, and bromocriptine, do not differ in their association with
psychiatric complications. 27,33,3,43,44 It is, therefore, likely that genetic variation plays a role in
the pathogenesis of the medication-induced side effects.
1.4 Genetics of response to dopaminergic medication
Research into the genetic causes of interindividual variability in impulsivity has implicated
polymorphisms in the catechol-0-methyltransferase (COMT), D2 receptor (DRD2), D3 receptor
(DRD3), and D4 receptor (DRD4) genes.s4 71 In healthy adults, increased risk for impulsivity is
linked with allelic forms that reduce synaptic levels of dopamine (at least one COMT Val
allele), 67,68,72-74 reduce receptor binding affinity for dopamine (presence of at least one DRD2
957C allele, presence of at least one ANKK1 TaqI Al allele,5 4-58 or presence of at least one DRD3
Ser alleles9 61 ,75), or reduce receptor coupling efficacy to second messenger proteins (presence
of D4 .7 allele).63 6 s,76,77 In short, healthy adults with reduced dopamine signaling, conferred by
the presence of one or more of the alleles noted above, show increased impulsivity.
COMT and DRD2-4 encode proteins that directly interact with anti-Parkinsonian medications:
The COMT enzyme is critical for inactivation of dopamine and levodopa in the PFC and is a
target of COMT inhibitors, such as entacapone and tolcapone.78 D2, D3, and D4 receptors
facilitate dopamine signaling between cells, have a high affinity for commonly prescribed
dopamine agonists (bromocriptine, pramipexole, pergolide, and ropinirole), 79~81 and likely
mediate the therapeutic effects of these drugs. 8 2 Thus, we reasoned that these polymorphisms
may underlie the psychiatric side effects of dopamine replacement therapy in PD.
Although the impact of COMT and DRD2-4 polymorphisms in modulating the risk for impulsivity
in PD has not been studied, results on the impact of COMT polymorphism on working memory
and attentional control are illuminating. Healthy adults with the Met/Met genotype, who have
high endogenous synaptic dopamine levels in the PFC, perform better on tests of executive
function, such as attentional control and working memory, than do healthy adults with the
Val/Val genotype, who have low endogenous synaptic dopamine levels. 83-86 This finding is
reversed in medicated PD patients: PD patients with the Val/Val genotype exhibit better
executive control than PD patients with the Met/Met genotype. 8 -~9 Similarly, administering d-
amphetamine, which increases dopamine transmission, to healthy adults with the Val/Val
genotype improves their performance on tests of executive function, while lowering the
performance of individuals with the Met/Met genotype.90 Likewise, tolcapone, a COMT
inhibitor commonly used in PD treatment, significantly improves the performance of healthy
Val/Val carriers on a measure of attentional set shifting, but it diminishes the performance of
healthy Met/Met carriers. 91
These seemingly contradictory effects of COMT polymorphism in medicated PD patients and
healthy adults are consistent with an inverted-U dopamine response curve, whereby too much
or too little dopamine results in cognitive dysfunction.92,9 3 The inverted-U dopamine response
curve was derived from experimental work on animals: When researchers injected a D1
receptor agonist into the PFC of rats performing a spatial working memory task, they found that
too much dopaminergic stimulation impaired spatial working memory performance. 94' 95
Similarly, elevated dopamine release and turnover (induced by administration of anxiogenic -
carboline FG7142) in PFC of rats and monkeys resulted in impaired performance on a spatial
working memory task.96
Consistent with the inverted-U hypothesis, injecting Di antagonists into the PFC of monkeys
performing an oculomotor delayed-response task showed that too little dopamine signaling
interfered with normal function.97 Similarly, Di receptor antagonists in rats interfered with
spatial working memory. 98 Electrophysiological studies in monkeys and rats have shown that
the inverted-U curve arises because low to moderate increases in prefrontal dopamine levels
suppress noisy task-unrelated neural firing, and thus focus task-relevant neural firing, while
higher amounts of dopamine silence neuronal firing in the PFC.99 101
Investigators have hypothesized that healthy adults with reduced dopamine signaling are
impulsive because they fall on the left side of the inverted-U curve (Figure 1.1). In contrast, the
dopamine overdose hypothesis posits that medicated PD patients who experience cognitive
side effects do so because they fall on the far right side of the curve. Differential vulnerability
of PD patients to medication-induced side effects, however, suggests that not all patients are
pushed to the right side of the curve by their dopaminergic medications. We hypothesize that
only those patients who carry candidate alleles that increase dopamine signaling (Table 1.1) fall
on the far right side of the curve. Because these patients effectively experience a dopamine
overdose, they are at increased risk for developing medication-induced psychiatric side effects.
We expect that PD patients with alleles that confer reduced dopamine signaling will have a low
risk for psychiatric side effects on medication because they fall near the peak of the curve after
dopamine replacement therapy.
In summary, we hypothesize that PD patients are at risk for medication induced psychiatric side
effects if they carry candidate alleles that increase dopamine signaling (Figure 1.2). Direct
support for this hypothesis comes from studies that have examined the impact of genetic
polymorphisms on hallucinations in PD. Two studies found that the frequency of DRD2 and
DRD3 genotypes that increase dopamine signaling are significantly higher in patients with
hallucinations compared to patients without hallucinations1 2 ,10 3 (but see 104' 105). Moreover, the
reduction of symptoms after decrease or cessation of dopaminergic treatment, 45 and the
successful treatment of hallucinations with medications that decrease dopamine signaling
(quetiapine, clozapine)106" 07 suggest that dopamine overdose gives rise to the medication-
induced negative side effects.
If our hypothesis is correct, it can shed light on the mechanisms by which dopaminergic
medications give rise to psychiatric complications in PD.
1.5 Candidate genes
We briefly review current knowledge on select polymorphisms in COMT, DRD2, DRD3, and
DRD4 that alter dopamine signaling (Table 1.1). Variations in these genes putatively determine
the pre-medicated position of an individual on the inverted-U dopamine curve. This knowledge
may be useful in predicting the impact of a right-ward shift on the curve due to exogenous
dopamine.8
1.5.1 COMT
The COMTVaI158Met polymorphism has a significant impact on the level of dopamine signaling
in the PFC.78 In 1957, Julius Axelrod discovered COMT, an enzyme that inactivates
catecolamines, such as dopamine. 108 The COMT gene is located on chromosome 22q11 and
encodes two proteins: a soluble form (S-COMT) and a membrane bound form (MB-COMT).109
MB-COMT is predominantly expressed in the brain while S-COMT is primarily present in the
periphery, including blood, kidney, and liver.n3 uo-u 3  In the brain, COMT is expressed
intraneuronally in postsynaptic neurons and in astrocytic processes surrounding dopaminergic
synapses, but the exact locus of COMT is not yet clear.11 4-11
6
Although COMT is ubiquitous in the brain,73 ,110 ,114 it is particularly important for inactivation of
dopamine in the PFC. Dopamine transporters (DAT), which provide the primary mechanism for
the clearance of dopamine from synapses in the striatum, are expressed at low levels in the PFC
and only at a distance from synaptic release sites. 7''1118
Several studies highlighted the critical role of COMT in deactivating dopamine in the frontal
cortex. 11'1 COMT knockout mice had significantly elevated dopamine levels in their frontal
cortices, but not in their striata.12 0 1'2 Administering levodopa to these COMT-deficient mice
significantly increased the PFC levels of dopamine, and the striatal levels of DOPAC (an MAO
metabolite) and levodopa, but not dopamine.119
Examination of the rate of formation of 3-methoxytyramine (created when COMT methylates
dopamine) in the rat revealed that COMT accounted for roughly 60% of dopamine turnover in
the PFC compared to 15% in the striatum. 2 Additionally, COMT mRNA, which encodes the
COMT enzyme, was expressed in humans and rats at higher levels in the PFC than in the
striatum.111 COMT appears to play a bigger role in primates than in mice and rats.12 3 For
example, DOPAC (an MAO metabolite) and HVA (metabolite of MAO and COMT) were present
in roughly equal amounts in the striatum and cerebrospinal fluid of rats and mice, whereas HVA
dominated DOPAC by at least a factor of 12 in primates.12 3,124
A functional G to A single nucleotide polymorphism in COMT (rs4680) results in a valine (Val) to
methionine (Met) amino acid change at codon 158 of MB-COMT (codon 108 of S-COMT). The
Val isoform was more stable and active than the one with Met at physiological
temperatures, 73, causing a 2 to 4 fold difference in COMT activity with the highest enzymatic
activity observed in Val/Val, followed by moderate activity Val/Met, and lowest activity in
Met/Met individuals. 73,12s The Met allele of COMT was not found in other mammals, including
great apes, and thus appears to be a recent mutation in evolutionary timeline that is unique to
humans.126 Decreased COMT activity putatively increases dopamine signaling in the PFC. 73
Thus, healthy carriers of Val/Val likely fall on the left leg of the inverted-U curve, while Met/Met
carries sit close to the peak.
1.5.2 DRD2
DRD2 C957T polymorphism alters the D2 receptor affinity for dopamine and thus may alter D2-
mediated dopamine signaling. D2 receptors are expressed at low levels across the cortex but
are abundant in subcortical regions, with the highest concentrations in the striatum and limbic
structures, such as the amygdala.127-13 The DRD2 gene, which codes for dopamine receptor D2,
is located on chromosome 11q23. DRD2 C957T (rs6277) is a synonymous polymorphism (i.e.,
the C to T substitution does not alter the encoded amino acid due to codon redundancy) that
surprisingly impacts D2 receptor function in vitro and in vivo.
In vitro cell cultures showed that the T allele was associated with decreased mRNA stability,
reduced receptor synthesis, and reduced dopamine-induced DRD2 up-regulation, possibly due
132to an alteration in the folding pattern of the mRNA as a result of the C to T substitution. In
contrast, subsequent studies using in vivo positron emission tomography in healthy adults
showed that the T allele was related to increased striatal D2 availability, driven by enhanced D2
binding affinity with each T allele (T/T > C/T > C/C). 3 3,13 4 The discrepancy between the in vivo
and in vitro results could have been due to the complexity of dopamine transmission regulation
in the human brain. 4  Still, increased binding affinity in the presence of the T allele could
potentially increase the level of dopamine signaling in the brain.
Most studies to date have focused on the impact of another D2 related polymorphism, Taq1A
(rs1800497), on cognition. PET studies showed that the Al allele of this polymorphism was
associated with a 30% to 40% reduction in D2 receptor density in striatum. 5 7 Newer reports,
however, showed that rs1800497 was located on kinase domain containing 1 (ANKK1) gene
downstream from the DRD2 gene, and that ANKK1 was not expressed in the brain. 135 Several
authors reported Taq1A polymorphism was in linkage disequilibrium with DRD2 C957T
polymorphism (d' = 0.832 to 1, indicating strong dependence), 32", 3 4 such that the Al allele of
Taq1A was disproportionately over- and under-represented among C/C and T/T carriers,
respectively. 3 4 136 We chose to study the DRD2 C957T polymorphism because it is likely that
Taq1A results are indirectly due to the C957T polymorphism.136
1.5.3 DRD3
D3 receptors are predominantly expressed in the nucleus accumbens, ventral tegmental area,
and limbic structures, such as amygdala 12 7 ,13 7,138 Because nucleus accumbens is a primary
target of the relatively preserved dopaminergic VTA, variations in D3 receptors may determine
whether this area will experience an overdose from exogenous dopamine.
DRD3 is located on chromosome 3q13. 3  Ser9Gly (rs6280) is a C to T substitution in the first
exon of DRD3 that results in a serine (Ser) to glycine (Gly) change at amino acid position 9 in the
extracellular N-terminus of the receptor. The Gly/Gly variant in Chinese hamster ovary cells has
a higher affinity for dopamine than the Ser/Ser and Ser/Gly variants, with no difference in
affinity between the later two forms.75 Using a selective D3 ligand, however, the authors found
that cells transfected with at least one Gly allele had a higher binding affinity for dopamine than
those transfected with the Ser allele.75 Similarly, in an in vitro setup with human embryonic
kidney cells, the Gly variant had a 4 to 5 fold increased affinity for dopamine compared to the
Ser variant. 40 In addition, cAMP inhibition was increased and MAPK signal duration was
prolonged with the Gly variant relative to the Ser variant, indicating that Gly variant is
associated with a more robust and prolonged activation of D3-mediated signal transduction
pathways. 4
1.5.4 DRD4
A polymorphism in DRD4 impacts the level of signaling of D4 receptors. These receptors are
primarily expressed in the PFC, hippocampus, amygdala, and hypothalamus.141 DRD4 gene is
located on chromosome 11p15 and has a 48 base-pair variable number of tandem repeats
(VNTR) polymorphism in its third exon.142 The number of repeats ranges from 2 to 11,
represented as D4.2 to D4 .11, respectively, causing a 32 to 176 amino-acid length difference in
the third intracellular loop of the receptor, a region that binds to second messenger proteins.14 1
The most common D4 alleles in humans are the D4 .2, D4.4, and D4.7, with 5%, 70%, 20%
prevalence, respectively.143,144 In Chinese hamster ovary cells, the D4 .7 had a blunted response
to dopamine compared to D4.2 and D4.4 : The potency of dopamine to inhibit cAMP formation
was reduced 2 to 3 fold with D4.7 compared to D4 .2 and D4 .4 .76 Thus, individuals with the 7-
repeat allele putatively fall on the right leg of the inverted-U curve.
1.6 Relevance to treatment of PD
The complications of dopaminergic treatment in PD include psychiatric disorders, such as
hallucinations and impulse control behaviors.27 33 ,3 s,43,14s-48 Two issues demand attention: the
greater vulnerability of certain patients to these side effects, and the role of genetic variation in
eliciting them. Here, we propose and test a mechanism by which psychiatric side effects of
dopamine replacement therapy can arise. By combining fine-tuned behavioral measures with
low-cost genotyping of select dopamine gene polymorphisms, this proposal will identify
biomarkers that distinguish patients who are at risk for medication-induced side effects.
Individualized care for these patients will reduce their risk of incurring irreversible financial and
personal costs due to medication-induced impulsivity and cognitive dysfunction.
The ultimate goal of PD research is to find the cause of and cure for the disease. In parallel to
research focused on this goal, it is essential to ensure that the available medication used to
ameliorate the motor symptoms of PD does not result in a degradation of the patients' quality
of life. Although few alternative treatments are available for patients who show increased risk
for hallucinations and impulsivity while taking dopaminergic medications, the identification of
this high-risk group will permit early detection of adverse behaviors.
Table 1.1 Summary of risk alleles
Proposed
effect on
Risk Functional dopamine
Gene Protein Polymorphism allele significance signaling
COMT Catechol-O- Val158Met Met Reduced dopamine Increase
methyltransferase catabolism72 73
Increased binding
DRD2 D2 receptor C957T T affinity for Increase
dopamine133,134
Increased binding
DRD3 D3 receptor Ser9GIy Gly affinity for Increase
dopamine75'140
DRD4 D4 receptor VNTR D Increased coupling to
adenylyl cyclase76 ,141  Increase
* without any DRD4 7-repeat alleles.
low HC+PD
HC
C. PD
E -
high
low Dopamine signaling high
Figure 1.1 Inverted-U dopamine response curve
The inverted-U dopamine response curve has been established in animals and
humans. Too little (left side of curve) and too much (right side of curve)
dopamine signaling result in cognitive dysfunction. Consistent with this view,
healthy adults with genotypes that reduce dopamine signaling (HC-) are
impulsive. We predict that PD patients with heightened dopamine transmission
(PD+) will be impulsive when receiving dopamine replacement therapy due to a
dopamine overdose effect.
Dopaminergic cell degeneration
Severe (90%) dopamine loss
in the nigrostriatal pathway
Motor symptoms
Moderate (30-50%) dopamine loss
in the mesocorticolimbic pathway
Cognitive symptomsI
Dopaminergic medication
based on severity of
motor symptoms
Reduced
motor symptoms
Patients with low dopamine
signaling do not experience
medication-induced
psychiatric side effects
Patients with high dopamine
signaling experience
dopamine overdose, causing
psychiatric side effects
Figure 1.2 Model for the development of medication-induced side effects in PD
The dose of prescribed dopaminergic medications is primarily based on the
severity of motor symptoms. In patients with increased dopamine signaling,
medication levels that reduce motor symptoms have the potential to overdose
the mesocorticolimbic pathway, which is much less affected than the
nigrostriatal pathway.
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2 Response inhibition
2.1 Introduction
Response inhibition is the capacity to stop a prepotent or habitual response. 149'1 i 0 Reduced
inhibition is a common feature of several clinical conditions-trichotillomania (repetitive hair
pulling), substance abuse, and ADHD. This impairment has, therefore, gained widespread
attention in recent years. 150,151
A common laboratory test of response inhibition, used in animals and humans, is the Stop
Signal Task, which measures the ability to inhibit a motor action after it has been initiated.
Participants are asked to respond as quickly as possible upon seeing a Go cue, and to inhibit this
action if the Go cue is followed by a Stop cue. The Stop signal is presented only in a minority of
trials, and thus responding becomes the prepotent action during the experiment. Inhibitory
ability is indexed by the Stop signal reaction time (SSRT), which estimates the amount of time
the brain needs to inhibit an ongoing action.
2.1.1 Neural substrates of response inhibition
The network of regions that mediates response inhibition includes the right inferior PFC
(Brodmann areas 44, 45, and 47), right pre-SMA, and right subthalamic nucleus of the basal
ganglia. Here, we briefly review the evidence in support of each node's role in response
inhibition.
In humans, damage to the right inferior PFC, but not the surrounding areas, resulted in slowed
SSRT, and this measure was correlated with the extent of damage in this region. 152 Further,
intracranial surface electrode recordings in humans showed increased activity in this region 100
to 250 msec after presentation of the Stop signal; this activity was grater when participants
inhibited their movement on the Stop trials than when they failed to do so.15 3
Damage to the right pre-SMA also resulted in slowed inhibition, without affecting reaction
times in trials without the Stop signal. 154 Functional MRI studies confirmed that the stopping
process activated the right inferior PFC and right pre-SMA, and that greater activity in the
inferior PFC was associated with better inhibitory ability.iss-is7 Unlike inferior PFC, activity in
the pre-SMA was not correlated with SSRT.1s8 Still, temporary deactivation of the right inferior
PFC or right pre-SMA using transcranial magnetic stimulation impaired inhibitory ability in
healthy adults.159"'60
Patients with cerebrovascular lesions in the basal ganglia had reduced inhibitory ability, though
the authors did not identify the exact location of the basal ganglia lesions.' 6 ' Functional MRI
studies in healthy adults revealed that activation of the right subthalamic nucleus of the basal
ganglia was associated with Stop, but not Go trials, and the strength of this activation was
correlated with SSRT. 55, 56, 58
Together, these studies suggest that the inferior PFC, pre-SMA, and subthalamic nucleus are
important nodes in the response inhibition network. 1s 1,16 2
2.1.2 Response inhibition in PD
Researchers have documented reduced inhibitory ability in PD patients. In a Go/NoGo task,
they responded more often than controls on trials when they should not have responded
(NoGo trials). 163 Further, SSRT was significantly longer in PD patients than in age-, sex-, and
education-matched controls. 164 This reduced inhibitory ability in PD was independent of
general slowing and cognitive impairment, 164 indicating a selective deficit in inhibitory ability.
One study showed that subthalamic nucleus stimulation in PD patients increased their
inhibitory control, 165 although another demonstrated that deep brain stimulation (DBS) induced
improvement was baseline dependent. Inhibitory ability increased in patients with the slowest
baseline SSRTs but deteriorated in those with normal baseline SSRTs.1 6 6 This finding is likely
due an inverted-U relation between subthalamic nucleus activation and inhibitory control
whereby DBS improved inhibitory ability in those with low baseline SSRTs, but impaired this
ability in participants who had normal baseline response inhibition.
2.1.3 Pharmacology and genetics of response inhibition
Pharmacological studies in animals suggest that dopamine plays a critical role in modulating
response inhibition: D-amphetamine, cocaine, and the dopamine reuptake inhibitor GBR 12909,
all of which increase dopaminergic neurotransmission, decrease response inhibition in rats,
measured by the number of premature responses in the 5-Choice Serial Reaction Time Task.167-
170 On this task, the dopamine antagonist alpha-flupenthixol blocked impulsivity induced by
intra-accumbens injection of d-amphetamine.167 Further, methylphenidate, which increases
synaptic levels of dopamine, reduced inhibitory deficits in children and adults diagnosed with
ADHD. 17-174
The pharmacological alteration of response inhibition was baseline dependent, and improved
inhibitory ability was limited to humans and rats with the worst performance at baseline.s
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This result is consistent with the inverted-U dopamine response hypothesis whereby only
individuals on the left-leg of the inverted-U curve (i.e., those with reduced dopamine signaling)
should improve when receiving dopaminergic medication.
Although hypoactivity of the serotonin system has traditionally been associated with forms of
impulsivity, such as aggression and suicidality,40' 18 0 modulation of serotonin did not impact
response inhibition measured by the Stop Signal Task. Specifically, dietary depletion of
serotonin precursor tryptophan 18, 18 2 or serotonin receptor blockade using a selective serotonin
reuptake inhibitor did not impact response inhibition in rats or healthy adults.183, 84
Genetic research also supports a role for dopamine in inhibitory control. A PET study showed
that the number of D2/D3 receptors was lower in impulsive rats compared to non-impulsive
ones.185 Healthy adults with at least one 7-repeat allele of D4, which reduces dopamine
signaling, had longer SSRTs compared to individuals without the 7-repeat allele, 63 and children
with ADHD who carried the 7-repeat allele of D4 required higher doses of methylphenidate for
symptom improvement.65 Healthy adults with at least one Met allele of COMT showed greater
SSRT-related brain activation in the right inferior PFC than those with the Val/Val genotype, 86
which is associated with better inhibitory control. 155'
186
In summary, converging evidence from studies in animals, healthy humans, and humans with
ADHD suggest that dopamine-induced changes in inhibitory ability follow and inverted-U curve,
and that this curve can arise as a function of natural variation in genes that regulate the level of
dopamine signaling.
2.1.4 Hypothesis
Building on prior work, we reasoned that variations in COMT, DRD2, DRD3, and DRD4 would
alter inhibitory ability in PD patients receiving dopamine replacement therapy. Two lines of
evidence support this hypothesis: first, the baseline-dependent influence of medication on
impulsivity, and second, the relation between genetic variation in the dopamine-system and
activation in the network mediating response inhibition. We hypothesized that patients who
carry genotypes that increase dopamine signaling would be more likely to experience deficits in
response inhibition due to a dopamine overdose. We addressed four specific questions: (1) Do
COMT Met/Met and Val/Met carriers have longer SSRTs than Val/Val carriers?, (2) Do DRD2 T/T
and C/T carriers have longer SSRTs than C/C carriers?, (3) Do DRD3 Gly/Gly carriers have longer
SSRTs than Ser/Gly and Ser/Ser carriers?, and (4) Do D4.7- carriers have longer SSRTS than D4 7+
carriers? We predicated that individuals with the risk variants of COMT (Met allele), DRD2 (T
allele), DRD3 (Gly allele), and DRD4 (absence of 7-repeat allele) would have longer SSRTs due to
dopamine overdose.
2.2 Materials and methods
2.2.1 Participants
We recruited 123 patients with idiopathic PD from the Movement Disorders Units at the
Massachusetts General Hospital and Brigham and Women's Hospital (Table 2.1). The inclusion
criteria were: United Kingdom Parkinson's Disease Society Brain Bank diagnostic criteria, 187
established by collaborating neurologists; mild to moderate disease indicated by Hoehn and
Yahr (H&Y) stages 1-111; taking dopamine replacement therapy; no significant cognitive deficits
indicated by Mini-Mental State Examination (MMSE) 188 score 26; at least 12 years of
schooling; and ability to give informed consent. The exclusion criteria were: history of a brain
disorder other than PD; serious medical conditions (e.g., cancer, diabetes, heart disease); and
severe depression indicated by a Beck Depression Inventory (BDI)189 score 18. All participants
gave written informed consent using procedures approved by the MIT Committee on the Use of
Humans as Experimental Subjects and by the Partners Human Research Committee.
Participants were taking their normal dose of dopaminergic medications and were optimally
medicated during testing. The self-identified racial and ethnic distribution of participants was:
122 White / not Hispanic or Latino and 1 Asian.
To compare dopaminergic medication among patients, each participant's dopaminergic drug
regimen was converted to a levodopa equivalent daily dose (LEDD) according to a
published 14 6' 190 formula: LEDD = levodopa/carbidopa regular (mg) + levodopa/carbidopa CR
(mg) x 0.75 + [levodopa/carbidopa (mg) + levodopa/carbidopa CR (mg) x 0.75] x 0.33 if on
entacapone or tolcapone + [levodopa/carbidopa (mg) + levodopa/carbidopa CR (mg) x 0.75] x
1.2 if on 10 mg selegiline (x 1.1 if on 5 mg selegiline) + bromocriptine (mg) x 10 + pramipexole
(mg) x 67 + requip (mg) x 20 + pergolide (mg) x 100.
2.2.2 Experimental design
On each trial, a left- or right-pointing green arrow appeared on a black computer screen (Figure
2.1). For Go trials, participants indicated the direction of this arrow by pressing the left or right
arrow key on the keyboard as fast as possible, using their preferred index and middle fingers,
respectively. The arrow stimulus remained on the screen until participants responded (max 2.5
sec). The next trial started after a 1.5 sec interval, during which the black screen remained
blank.
On 25% of the trials, Stop trials, the arrow stimulus was replaced with a Stop signal (a red
vertical bar) after a variable delay (Stop signal delay). We asked participants to inhibit their
response when the Stop signal appeared. If they did so, the red bar remained on the screen for
2.5 sec. If participants erroneously pressed one of the arrow keys, the red bar disappeared
immediately. The next trial started after a 1.5 sec interval.
The Stop signal delay started at 250 msec and was adjusted using an adaptive staircase
method. 191 If participants successfully inhibited their response on a Stop trial, the Stop signal
delay was increased by 50 msec the next time a Stop signal appeared, thus making it harder to
exert inhibitory control. If participants failed to inhibit themselves on a Stop trial, the Stop
signal delay was decreased by 50 msec for the next Stop trial. This algorithm ensured that each
participant could inhibit roughly 50% of all Stop trials by the end of the experiment. This design
allowed each participant to perform at his or her own inhibition threshold, equated the level of
difficulty experienced by participants, and controlled for individual differences in speed of
responding. 64
We explained to the participants that they would not always be able to inhibit their response
on Stop trials because the computer would adjust the difficulty of the task according to their
performance level. We also asked them not to delay their response in anticipation of the Stop
signal, but to inhibit their response when they saw the Stop signal. Participants completed 180
go and 60 Stop trials in 5 blocks with each block containing 36 Go and 12 Stop trials (240 trials
total with an equal number of left- and right-pointing arrows in each block). Data analysis was
limited to the fifth block to allow the staircase algorithm to converge on each participant's
inhibitory threshold. Limiting the SSRT analysis to the fifth block ensured that all participants
were performing at the same SSRT threshold-defined as the amount of advance warning a
participant requires to be able to inhibit a habitual response 50% of the time-before they
were compared with each other.
2.2.3 Genotyping
We extracted DNA from the venous blood of all participants using a QlAcube robotic
workstation (Qiagen, Hilden, Germany). Aliquots of DNA were sent to Partners HealthCare
Center for Personalized Genetic Medicine for genotyping. The DRD2 C957T (rs6277), DRD3
Ser9Gly (rs6280), and COMT Val158Met (rs4680) polymorphisms were genotyped using
Sequenom hME chemistry, and DRD4 exon Ill VNTR was genotyped using a previously published
protocol.77 In our sample, 23, 69, and 31 patients carried the COMT Val/Val, Val/Met, and
Met/Met genotypes, respectively. The DRD2 C957T break down was 21 C/C, 62 C/T, and 42
T/T. These distributions did not depart from the Hardy-Weinberg equilibrium (COMT: 2 =
1.975, df = 1, p = 0.160; DRD2: Xj = 0.132, df = 1, p = 0.716), indicating that allele frequencies
were in equilibrium in our cohort. Because only 8 and 12 participants fell in the D4 7+ and DRD3
C/C groups, respectively, we excluded DRD3 and DRD4 from further analyses.
2.2.4 Statistical analysis
The principal dependent variable was the SSRT, measured by subtracting the average Stop
signal delay from the average correct Go reaction time in the final block.191 We also examined
the participants' reaction times and error rates on Go trials. A univariate analysis of covariance
(ANCOVA) compared each variable of interest among different genetic subgroups. We included
age and sex in the ANCOVA as covariates because previous research uncovered age and sex
differences in cognitive control ability 92 19 3 and COMT enzyme activity.73 We also included
LEDD, disease duration, and H&Y stage as covariates in the model to control for differences
among participants in dopamine replacement dosage and the severity of motor symptoms.
To examine the impact of training on inhibitory ability, we compared SSRTs in the first and fifth
blocks of the experiment. Because the staircase algorithm may not have converged to the 50%
inhibitory threshold in the first block for all participants, we first corrected SSRTs for inhibition
thresholds-defined as the number of successfully inhibited trials-in each block, and then
carried a repeated measures ANCOVA on the adjusted SSRTs. We followed significant results
with post-hoc tests. All data were analyzed using MATLAB 2009a (MathWorks Inc., Natick, MA)
and SPSS 11.5 (SPSS Inc., Chicago, IL).
2.3 Results
We characterized the participants in terms of age, sex, PD duration, H&Y stage, LEDD, number
on agonists, MMSE, BDI, and education across COMT genotypes (Table 2.2). A significantly
larger number of DRD2 C/C individuals were taking dopamine agonists as compared to C/T and
T/T carriers (X2 = 6.915, df = 2, p = 0.032). Individuals with the C/T genotype of DRD2 were
slightly, but significantly, older than C/C and T/T patients (C/C: M = 63.4, SD = 8.7; C/T: M =
68.6, SD = 8.4; T/T: M = 64.4, SD = 8.5; C/T vs. C/C : p = 0.048; C/T vs. T/T: p = 0.048). This age
difference was taken into account by including age a covariate in all analyses. Patients were
well matched on all other characteristics across DRD2 genotypes (Table 2.3).
Because the green arrow in the Go trials was visible only for 2.5 seconds, we examined whether
any participants missed this response window. Among the 123 participants, 117 (95.1%) never
missed the window while 6 (4.9%; 2 COMT Val/Met & DRD2 C/C, 3 COMT Val/Met & DRD2 T/T,
1 COMT Met/Met & DRD2 T/T) participants missed the window on only a single Go trial. The
number of successfully inhibited trials did not differ statistically among DRD2 and COMT
genotypes.
We used a univariate ANCOVA with SSRT as the dependent variable and genotype as the
independent factor to examine effect of COMT variation on SSRT (Figure 2.2A). Age, sex,
disease duration, total LEDD, and H&Y stage were covariates in the ANCOVA. The main effect
of COMT on SSRT was significant (F2,115 = 3.673, p = 0.028, i 2 = 6.0%). Planned post-hoc
comparisons revealed that Val/Met and Met/Met participants had significantly higher SSRT
thresholds than Val/Val individuals (Val/Met vs. Val/Val: p = 0.004 one-sided; Met/Met vs.
Val/Val: p = 0.018 one-sided). The effect of COMT on accuracy (F2,115 = 0.518, p = 0.597) and
reaction times (F2,115 = 1.852, p = 0.162) on Go trials was not significant (Figure 2.2B and C). The
effect of DRD2 on SSRT (F2,115 = 0.336, p = 0.715), Go trial accuracy (F2,115 = 2.696, p = 0.072),
and Go trial reaction times (F2,115 = 0.437, p = 0.647) was not significant.
To examine whether COMT variation interacted with training, we compared SSRTs in the first
and fifth blocks. Because SSRT thresholds were significantly different between the two blocks
(p = 4.04 x 1012), we first corrected the SSRTs in the two blocks for this threshold difference:
For each block, we ran a regression with the SSRT as the dependent variable and the
percentage of successfully inhibited trials as the independent variable. Then we compared the
standardized residuals from the two regressions. We ran a repeated measures ANCOVA with
the standardized residuals as the dependent variables, and COMT genotype as the between-
subjects factor. In both blocks, Val/Val carriers had lower standardized residuals (indicating
better inhibitory ability) than those with at least one Met allele. Neither the main effect of the
experimental block (F1,115 = 1.085, p = 0.300), nor the interaction between block and genotype
(F2,115 = 0.853, p = 0.429) were significant.
2.4 Discussion
This study examined whether polymorphisms in COMT, DRD2, DRD3, and DRD4 modulate
inhibitory ability in PD. We addressed four specific questions: (1) Do COMT Met/Met and
Val/Met carriers have longer SSRTs than Val/Val carriers?, (2) Do DRD2 T/T and C/T carriers
have longer SSRTs than C/C carriers?, (3) Do DRD3 Gly/Gly carriers have longer SSRTs than
Ser/Gly and Ser/Ser carriers?, and (4) Do D4.7- carriers have longer SSRTS than D4 .7+ carriers?
We predicated that those individuals with variants that increase dopamine signaling would
have reduced inhibitory ability due to a dopamine overdose in networks that are relatively
preserved in the early stages of the PD. We found that patients who carried at least one Met
allele of COMT, which confers increased dopamine levels in the PFC, had longer SSRTs than
non-carriers. This reduction in inhibitory control was not accompanied by changes in accuracy
or reaction times in trials without a Stop signal, indicating that increased SSRT was not due
changes in performance or a general slowing of reaction times. Unlike COMT, DRD2 variation
did not alter the SSRT. Due to sample sizes, we were unable to examine the influence of DRD3
and DRD4 on the SSRT.
The major finding of this experiment was that the Met allele of COMT resulted in a selective
decrease in inhibitory ability in PD patients taking dopamine replacement therapy. Critically,
this cognitive deficit was consistent with our prediction based on previous results showing an
inverted-U relation between dopamine signaling and inhibitory ability. This finding highlights
the future possibility of optimizing an individual's dopamine replacement therapy regimen
based on their unique genetic profile.
Impact of COMT Val158Met polymorphism on SSRT
The observed effect of the COMTVal158Met polymorphism is consistent with the known neural
substrates of response inhibition. Investigators have shown that normal function of the PFC,
particularly right inferior frontal gyrus, is essential for successful response inhibition.1" 1
Further, too much dopamine in the PFC results in a general reduction in neuronal activity.99-101
In an in vitro study in mice, investigators showed that application of high concentrations of
dopamine to the PFC significantly reduced the number of action potentials produced by
pyramidal neurons.100 Similarly, in well trained monkeys performing a spatial working memory
tasks, high levels of D1 agonists significantly reduced the delay period activity of pyramidal
neurons.99' 101 Thus, it is likely that those with at least one Met allele of COMT had slowed
SSRTs because of a reduction of neural activity in the PFC due to a dopamine overdose. We
cannot rule out the possibility that the impact of COMT was due to its action at other nodes of
the inhibitory network (e.g. pre-SMA or STN). Future functional imaging studies on the impact
of the COMT Val158Met variation on response inhibition in PD patients may be able to localize
specific nodes of interaction between dopamine replacement therapy and COMT variation.
No link between DRD2 C957T polymorphism and SSRT
The lack of a DRD2 effect on response inhibition was surprising. D2 receptors are densely
expressed in the basal ganglia (including caudate and putamen), which constitute one of the
nodes of the response inhibition network. A previous study reported that healthy adults with
variants of DRD2 that increased the expression of D2 receptors had better inhibitory control
than those with reduced D2 expression levels.194 Similarly, alcoholic carriers of the Al allele of
the ANKK1 Taq1A polymorphism, which is in linkage disequilibrium with DRD2 C957T and is
associated with 30% to 40% reduced D2 receptor density in the striatum, had worse inhibitory
control than A2/A2 carriers. 195 Further, PD patients who performed at the same level as
controls in the Go/NoGo task had increased activity in the right caudate relative to controls,
highlighting the importance of striatum for response inhibition in PD.196
No interaction between COMT and DRD2 on SSRT
Several investigators have shown a significant interaction between COMT and DRD2
polymorphisms in healthy adults. In a word serial position test of memory, those with COMT
Val/Val and DRD2 C/C genotypes performed worse than those with Met/Met and T/T
genotypes.197 Further, Met carries had significantly better working memory manipulation
performance relative to Val/Val carriers, but only when they did not carry the Al allele of the
ANKK1 TaqlA.1 98 Thus, to test for a possible interaction, we ran an ANCOVA with SSRT as the
dependent variable, COMT and DRD2 as independent variables, and age, sex, disease duration,
disease severity, and LEDD as covariates. The main effect of COMT remained significant in this
model (p = 0.043), but as before, the main effect of DRD2 was not significant. We did not find
an interaction between COMT and DRD2. Although this finding could be due to our small
sample size (only 3 people were Val/Val and C/C carriers), the results suggest that the
COMTCaIl158Met, and not DRD2 C957T, variation is the critical determinant of inhibitory ability
in PD patients who take dopamine replacement therapy.
Training did not alter inhibitory ability among COMT genotypes
An interesting question was whether PD patients could be trained to shorten their time to
inhibit their response. To examine this issue, we compared the SSRTs in the first and fifth
blocks of our experiment. If training were effective, then SSRTs in the fifth block would be
shorter than SSRTs in the first block. This finding would indicate that due to training, the
participants needed less time to successfully inhibit a habitual response in the fifth block,
relative to the first block. COMT Val/Val carriers had lower SSRTs (adjusted for the difference in
stopping threshold between the two blocks) than those with at least one Met allele in both
blocks. The main effect of the experimental block and the interaction between block and
genotype were not significant (p > 0.05). These results highlighted that training did not alter
inhibitory ability among COMT genotypes.
DRD3 and DRD4
We were unable to examine the influence of DRD3 and DRD4 variation on inhibitory control
due small sample sizes. Because studies in healthy adults have shown a significant impact of
DRD4 variation on inhibitory ability, this polymorphism may play an important role in PD
inhibitory ability as well.6 3 D3 receptors are densely expressed in the ventral striatum, which is
spared from dopamine loss in the early stages of PD.127,137,138,199 Because most dopamine
agonists have a high affinity for D3 receptors,80'200 variations in DRD3 may play a crucial role in
determining individual risk for dopamine-induced side effects. Future studies with larger
sample sizes should examine the importance of these two genes for cognition in PD.
Conclusions
The dopamine overdose hypothesis posits that dopamine replacement therapy overloads
networks that are relatively spared from dopamine cell death in PD, thus adversely affecting
the functions carried by them. Here, we advance this hypothesis by showing that
medication-induced changes in behaviors mediated by these circuits also depend on variation
in genes of the dopamine system. Specifically, we showed that participants with at least one
Met allele of COMT, which is associated with increased dopamine levels in the PFC, had
significantly worse inhibitory ability than Val/Val carries. These findings suggest that Met
carriers have an increased risk for developing impulse control behaviors when taking dopamine
replacement therapy.
Table 2.1 Characteristics of PD patients who completed the Stop Signal Task
Variable PD patients
No. of participants 123 (80M; 43F)
Age (yrs) 66.3 (8.7)
PD duration (yrs) 5.5 (3.8)
Stage 1 17
H&Y Stage 2 98
Stage 3 8
LEDD (mg/day) 610.9 (444.3)
% taking agonists 55.3%
MMSE 28.2 (1.3)
BDI 6.1 (4.1)
Education (yrs) 16.7 (2.9)
Results are presented as mean (SD), number, or percentage.
Characteristics of COMT subgroups in the Stop Signal Task
Variable COMT P
Val/Val Val/Met Met/Met
No. of participants 23 69 31
Age (yrs) 68.0 (6.7) 65.8 (8.7) 66.3 (10.2) 0.600 §
Sex M:F 13:10 44:25 23:8 0.382 *
PD duration (yrs) 5.0 (3.8) 5.1 (3.8) 6.7 (3.8) 0.116 §
Stage 1 2 9 6
H&Y Stage 2 19 55 24 0.770 E
Stage 3 2 5 1
LEDD (mg/day) 557.9 (378.4) 595.4 (434.7) 685.0 (510.8) 0.533 §
% taking agonists 52.2% 56.5% 54.8% 0.935
MMSE 28.0 (1.5) 28.2 (1.3) 28.3 (1.3) 0.577 §
BDI 5.8 (3.7) 6.0 (4.0) 6.7 (4.5) 0.688 §
Education (yrs) 16.7 (3.4) 16.7 (3.0) 16.5 (2.4) 0.951 §
§ ANOVA; V Chi square test; E Fisher's exact test.
Results are presented as mean (SD), number, or percentage.
Table 2.2
Characteristics of DRD2 subgroups in the Stop Signal Task
Variable
No. of participants
Age (yrs)
Sex M:F
PD duration (yrs)
Stage 1
H&Y Stage 2
C/C
21
63.4 (8.7)
14:7
5.5 (3.3)
6
15
DRD2
C/T
62
68.6 (8.4)
42:20
5.6 (4.0)
7
50
Stage 3 0 5
LEDD (mg/day) 616.4 (325.1) 582.6 (455.
% taking agonists 81.0% 48.4%
MMSE 28.5 (1.2) 28.3 (1.3)
BDI 6.1 (3.4) 5.7 (4.1)
Education (yrs) 17.2 (2.3) 16.9 (3.1)
§ ANOVA; M Chi square test; E Fisher's exact test.
Results are presented as mean (SD), number, or percentage.
Significant results are indicated in bold font.
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64.4 (8.5)
24:16
5.3 (3.9)
4
33
3
651.9 (485.1)
52.5%
27.8 (1.3)
6.8 (4.4)
16.2 (2.9)
8)
0.013
0.715
0.909§
0.267 E
0.746
0.032
0.070
0.404
0.324 §
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Figure 2.1 Sequence of events in the Stop Signal Task
Participants were instructed to respond in the Go trials and try to inhibit their
responses in the Stop trials. Example sequence of events in the Stop Signal Task:
hit left arrow key; hit right arrow key; suppress action to hit right arrow key after
seeing the Stop signal (red vertical bar).
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Figure 2.2 SSRT as a function of COMT genotypes
A) Patients with at least one Met allele had a significantly longer SSRT compared
to Val/Val carriers. B) The groups did not differ in accuracy. C) The groups did
not differ in reaction times on Go trials. Error bars depict SEM. * p = 0.004 one-
sided; # p = 0.018 one-sided.
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Figure 2.3 SSRT as a function of DRD2 genotypes
A) DRD2 subgroups did not differ in SSRT. B) The groups did not differ in
accuracy. C) The groups did not differ in reaction times on Go trials. Error bars
depict SEM.
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3 Delay of gratification
3.1 Introduction
Delay of gratification is the ability to exert self-control by overriding the impulse to choose a
small immediate reward instead of a larger delayed one.26,40 This dimension of impulsivity is
typically examined in the laboratory using the delay discounting task, whereby participants
decide between smaller-sooner and larger-later choices. Humans and animals tend to discount
the value of future rewards hyperbolically, often resulting in a preference for the more
immediate option.201
Discounting, a robust effect, has been documented with primary (food, juice) and real or
hypothetical secondary (money, gift voucher) rewards. 202-204 Participants vary considerably in
the level of discounting of delayed rewards. Steeper discounting curves, corresponding to a
stronger desire for immediate choices, are considered impulsive. This finding is common
among smokers, 205 ,206 obese women, 207,208 and individuals with impulse control disorders such
as heroin, cocaine, and methamphetamine addicts, 20 9-211 alcoholics,212 ,213 pathological
gamblers,21 4 and individuals with ADHD. 21s,216 Steeper discounting curves are a risk factor for
substance abuse, alcohol addiction, and smoking.217 22
3.1.1 Neural substrates of delay discounting
Lesion and fMRI studies have identified a network of brain regions that are engaged during
delay of gratification judgments. Humans with bilateral medial orbitofrontal cortex (OFC)
damage, due to traumatic brain injury or ruptured aneurysms, showed a significantly increased
preference for impulsive choices, relative to controls and lesion controls with damage to
regions beyond the PFC.202 Normal function of medial OFC may be necessary for selection of
delayed choices because damage to non-OFC regions of the PFC did not alter discounting.2 In
particular, participants with ventromedial, but with some sparing of the medial OFC, or
dorsolateral PFC damage performed discounting tasks similarly to controls and those with
damage to cortex posterior to the central sulcus. 22
Early lesion studies in rats provided conflicting accounts of OFC's role in temporal discounting.
Two laboratories22 ,224 showed that bilateral OFC lesions resulted in a preference for smaller-
sooner rewards, while another found that OFC lesions increased preference for larger-later
ones. 22 Subsequent studies provided an explanation for these discrepant results. 226,227
Investigators noticed that baseline levels of impulsivity differed among the three studies, and
that a cue marked that gap between the selection of the larger-later reward and its delivery in
the first two studies but not in the third one.22227 In a well-controlled experiment with rats,
researchers showed that delay discounting performance depended on baseline levels of
impulsivity and on the presence or absence of a cue between selection and delivery of the
delayed rewards: OFC inactivation increased impulsivity in less impulsive rats in the presence of
a cue, but decreased impulsivity in more impulsive rats when no cue was present. 226
The interaction between the cue and discounting may have been due to the cues acting as a
conditioned reinforcer: It is possible that the presence of the cue highlighted, to the less
impulsive animals, that they had chosen the delayed signal and now must wait for their reward,
thus reducing the desirability of the delayed reward.228 Given the role of OFC in monitoring and
updating subjective reward values and integrating this information with goals,2 29 the absence of
the cue may have deprived the OFC-lesioned impulsive animals from a salient teaching signal
that would allow them to lower their internal value of the delayed reward through non-OFC
compensatory mechanisms, thus making them appear less impulsive.' 2 4
Lesion studies have also identified the ventral striatum, specifically the nucleus accumbens core
and basolateral nucleus of the amygdala (BLA), as two other nodes in the delay of gratification
network. Selective lesions of these sites increased the preference for smaller-sooner rewards
over the larger-later ones.22s,231,232 Importantly, the impulsive lesioned animals were able to
discriminate between the small and larger rewards and preferred the larger rewards at zero
delay. This finding suggests that the nucleus accumbens core and BLA may maintain the
subjective value of rewards across the delay.22s,233
Two accounts of the neural substrates of delay discounting have emerged from fMRI
experiments in humans. McClure and colleges (2004) reported that limbic regions (including
right ventral striatum, right medial OFC, and medial PFC) were more active, relative to baseline,
when healthy young adults chose between immediately available rewards or delayed
rewards. 204,4 In contrast, they found that regions known to mediate cognitive control
(including right dorsolateral PFC, right ventrolateral PFC, right lateral OFC, and posterior
parietal cortices) were engaged when participants made choices between immediate versus
delayed and delayed versus more-delayed rewards. Further, activity in cognitive control areas
was correlated with choice difficulty, and these areas were more active than limbic regions
when participants chose larger-later over smaller-immediate rewards. 204,23 4
Another group obtained similar results using a slightly modified task.23 s McClure and his team
interpreted these findings as evidence for two separate neural systems in the brain: an
impulsive "f-system" corresponding to the limbic areas and a more patient "6-system".204,24,2
As discussed in the Chapter 1, cortex and basal ganglia are connected via distinct functional
loops.19 The P- and 6-systems map on to the cognitive/motor and limbic loops, respectively.
Thus, these results suggest that activity in the limbic loop would enhance the likelihood of
impulsive choices, while motor and cognitive loop activations would contribute to selection of
non-impulsive choices.
Some investigators have noted that the P-6 account is inconsistent with human studies showing
that medial OFC lesions increased impulsive choices.202 They argue that if activation of the -
system led to more impulsive choices, then, contrary to empirical results, removal of the medial
OFC should have strengthened the 6-system relative to the P-system and thus should have
reduced impulsivity.
In contrast to McClure's two component model, Kable and colleges (2007) provided evidence
for a unitary delay of gratification network.2 37,238 They showed that fMRI activity in left ventral
striatum, left medial PFC, and left posterior cingulate cortex correlated with the subjective
value of delayed rewards: Activity in these regions increased as the magnitude of the rewards
increased or as the delay to rewards decreased.
They also noted that McClure's finding of increased activity in ventral striatum, medial OFC, and
medial PFC in presence of immediately available options did not necessarily imply that these
regions only value immediate rewards. 237 Because the subjective value of immediate rewards
was higher than later rewards, the one-component model would predict that these regions
would show a stronger BOLD signal on trials with an immediately available option compared to
trials with only delayed options.m
The unitary network is also consistent with animal studies showing that lesions in the nucleus
accumbens resulted in increased impulsivity. If higher activity in the accumbens signals higher
expected future rewards and induces the animal to reject the small-immediate reward, then
removal of the accumbens would deprive the animal of this signal and result in increased
impulsivity.51 ,231
Additional evidence for the one-component model showed that activity in a similar set of
regions was correlated with discounted value of future rewards. 239 Ballard and co-workers
(2009) provided further evidence for the unitary model using a delay discounting task that
could distinguish neural activity due to the magnitude and delay of future rewards. 240 They
found that activity in the limbic loop (right nucleus accumbens, left medial PFC, and bilateral
posterior cingulate cortex) was positively correlated with reward magnitudes, while activity in
the cognitive loop (left dorsolateral PFC, right posterior parietal cortex, and left temporal-
parietal junction) was negatively correlated with reward delays.240 Critically, they
demonstrated that neural activity in all identified areas correlated with participants'
discounting rates.240
In summary, converging evidence indicates that specific regions within the limbic and cognitive
loops, which are a target of dopaminergic projections, are critically involved in delay of
gratification calculations. 204,23 4,237 2 41 Because VTA is relatively spared from degeneration in the
early stages of PD, exogenous dopamine may alter activity in this network, resulting in
maladaptive discounting of future rewards.
3.1.2 Delay discounting in PD
Few studies have examined delay of gratification as a measure of impulsivity in PD because
reports of increased impulsivity in PD were absent from the literature until the early 2000s. 242
In one study, Voon and colleagues (2010) examined delay of gratification in PD patients with
impulse control behaviors (compulsive shopping or pathological gambling) and those without
them.243 They found that discounting rates were not significantly different between the two
groups when they were off pramipexole, a D2/D3 receptor agonist. When the patients were
taking pramipexole, however, only those with impulse control behaviors showed increased
discounting rates.243
A subsequent study used an expanded set of impulsive behaviors (binge eating, compulsive
medication use, compulsive shopping, hypersexuality, pathological gambling, and punding), and
confirmed the observation that temporal discounting is increased in PD patients with impulse
control behaviors.244 This study did not find an effect of medication on impulsivity. Critically,
they found that stimulus-reward association learning was preserved in patients with impulse
control behaviors, but not in those without. This finding suggests that elevated discounting of
future rewards in PD patients with impulse control behaviors is not due to abnormal reward
learning. 244 Rather, these data imply that aberrant dopaminergic signaling in the ventral
striatum and limbic loop likely result in decreased tolerance for delayed choices.244 This
reasoning is consistent with two lines of evidence: animal studies showing increased impulsivity
with limbic loop lesions; 245 and fMRI results in healthy young adults showing that levodopa
significantly increased activity in the limbic loop and markedly enhanced preference for smaller-
sooner rewards. 239
3.1.3 Pharmacology and genetics of delay discounting
Animal and human studies have consistently shown that dopaminergic agents can modulate the
delay of gratification. Two medications that increase dopaminergic neurotransmission, d-
amphetamine and methylphenidate, successfully reduced impulsivity in patients with ADHD.41
Low doses of these agents also decreased delay discounting in healthy adults. 246,2
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In rats, acute administration of moderate doses of d-amphetamine reduced discounting in the
presence of a conditioned reinforcer. 228,248,249 Acute administration of d-amphetamine in the
absence of a conditioned reinforcer, 228 or long term administration of large doses of this drug,
however, significantly decreased the value of delayed rewards. 249 Critically, impact of these
agents also depended on baseline levels of impulsivity: d-amphetamine increased discounting
in rats with low baseline levels of impulsivity, but had the opposite effect in rats with high
baseline levels of impulsivity.179
Di and D2 receptors can both modulate discounting rates. Investigators reported that systemic
injections of the D1/D 2 antagonist a-flupenthixol, D2 antagonist raclopride, and D3 agonist 7-OH-
DPAT, and local medial PFC infusions of the D, antagonist SCH 23390 and D1/D 5 agonist SKF
38393 increased impulsive choices in rats. 226 ,2 28,248,250,25 Moreover, nucleus accumbens shell
expression levels of DRD5 and medial PFC expression levels of DRD1, DRD5, and calcyon (whose
protein product regulates D, receptor affinity for dopamine) were significantly greater in rats
with high baseline levels of impulsivity compared to less impulsive rats. 25 This study, however,
did not find a relation between DRD2, DRD4, and COMT expression levels and impulsivity. This
negative result does not contradict the association between polymorphisms in these genes and
impulsivity because gene expression levels do not predict receptor density or function.
Pharmacological evidence that D2-a primary target of dopaminergic drugs used in PD-plays a
role in discounting judgments is consistent with genetic results showing that humans with
substance abuse problems, who typically have a reduced ability to delay gratification, have
decrease striatal D2 receptor densities.2s2-2s4 Voon et al.'s report243 that a D2JD 3 agonist
pramipexole increased impulsivity in PD patients with existing impulse control behaviors lends
credence to this hypothesis.
The finding that dopaminergic agonists and antagonists can alter impulsivity underscores the
nonlinear relation between impulsivity and dopaminergic signaling: positive or negative
deviations from optimal dopamine concentrations can result in maladaptive behavior. Further,
the interaction between dopaminergic agents and baseline levels of impulsivity suggests that
genetic factors play an important role in the behavioral outcome of dopamine replacement
therapy.
No consensus exists on whether serotonin plays a role in delay discounting. Dietary serotonin
depletion studies in healthy humans found no effects255 ,256 or minor ones. 257 Similarly, animal
studies have not produced consistent results. One study examined the relative contribution of
the dopaminergic and serotonergic systems in a discounting task where the cost was either a
delay or physical effort.25 s Animals treated with the D2 receptor antagonist, haloperidol, chose
the smaller-sooner reward more often than controls. The treated animals also chose the high
effort/high reward choice significantly less often than control animals. The investigators found,
however, that selective blockade of tryptophan hydroxylase, a rate limiting enzyme in synthesis
of serotonin, only impacted delay-based decisions: serotonin depleted rats were more likely to
chose the smaller-sooner reward over the larger-later reward, but their preference for high or
low effort rewards was similar.
Other studies, however, did not find a relation between serotonin and delay discounting. For
example, investigators found no differences in delay of gratification between serotonin
depleted rats and controls. 25 9 This finding was confirmed in a second study that further showed
serotonin depleted animals, particularly ones with high baseline levels of delay discounting, had
a muted response to d-amphetamine treatment.26 0 The serotonin-dependent response to d-
amphetamine treatment indicates an interaction between serotonin and dopamine.
In vivo microdialysis experiments in rats have elucidated the differential contributions of
dopamine and serotonin to delay of gratification judgments. Researchers found that serotonin
levels increased in the medial PFC, but not in the OFC, whereas DOPAC, a metabolite of the
dopamine, levels increased in both medial PFC and OFC of rats performing a delay discounting
task for food rewards. 26 1 Together, these results hint at a complex interaction between
dopaminergic and serotonergic systems in mediating delay of gratification.
Healthy adults with candidate alleles that reduce dopamine signaling are more likely to choose
smaller-sooner rewards than individuals who do not carry these alleles.58'66 COMT Val/Val
genotype was associated with increased discounting compared to Val/Met and Met/Met
genotypes in healthy adults and abstinent alcoholics. 66 In addition to being more impulsive,
Val/Val carriers had significantly increased brain activity in the posterior parietal cortex and
dorsal PFC relative to Val/Met heterozygotes,66 suggesting that the Val allele results in
inefficient cortical function due to reduced dopamine levels.
Genes that regulate D2 receptors also play a role in delay discounting: Healthy adults with at
least one Al allele of the ANKK1 TaqI A, which is associated with reduced D2 receptor density in
the striatum, had steeper discounting curves than A2 carriers. 58 Further, DRD2 interacted with
DRD4 such that individuals with both Al and D4.7 had the steepest discounting curves.58
In summary, healthy adults with COMT, DRD2, and DRD4 polymorphisms, which putatively
reduce dopamine signaling, have increased discounting rates.
3.1.4 Hypothesis
We tested the hypothesis that PD patients who carry the genotypes of COMT, DRD2, DRD3, and
DRD4 that increase dopamine signaling are more likely to show reduced ability to delay
gratification when receiving dopamine replacement therapy. Several lines of evidence support
this hypothesis. First, the neural network that subserves delay of gratification judgments
receives dense dopaminergic inputs from the ventral striatum, which is relatively spared from
neurodegeneration in the early stages of PD. Second, deviations from optimal dopamine levels
in this network result in reduced ability to delay gratification. Third, impact of dopaminergic
agents on delay of gratification depends on baseline levels of impulsivity, which are partly
determined by variations in genes that regulate the dopaminergic system.
Investigators have shown that healthy adults with genotypes that reduce dopamine signaling
are more likely to choose smaller-sooner rewards than individuals who do not carry them. 8 '66
Because of the inverted-U relation between dopamine signaling and cognition, we
hypothesized that this pattern would be reversed in PD patients receiving dopamine
replacement therapy due to dopamine overdose in preserved brain circuits: Patients with the
candidate genotypes that increase dopamine signaling would show reduced ability to exert self-
control and delay gratification, compared to patients who are non-carriers. We addressed four
specific questions: (1) Do COMT Met/Met and Val/Met carriers have steeper discounting
curves than Val/Val carriers?, (2) Do DRD2 T/T and C/T carriers have steeper discounting curves
than C/C carriers?, (3) Do DRD3 Gly/Gly carriers have steeper discounting curves than Ser/Gly
and Ser/Ser carriers?, and (4) Do D4 .7- carriers have steeper discounting curves than D4 .7+
carriers? We predicated that individuals with the risk variants of COMT (Met allele), DRD2 (T
allele), DRD3 (Gly allele), and DRD4 (absence of 7-repeat allele) would have increased
discounting stemming from dopamine overdose.
3.2 Materials and methods
3.2.1 Participants
We recruited 128 PD patients who satisfied the inclusion and exclusion criteria described in
chapter 2 (Table 3.1). The self-identified racial and ethnic distribution of participants was: 125
White / not Hispanic or Latino, 2 White / Hispanic or Latino, and 1 Asian.
3.2.2 Experimental design
Participants made a series of choices between a $1,000 hypothetical reward delivered after a
variable delay and a lesser reward available immediately (e.g., "Would you prefer to have $600
now or $1,000 after a week?"). The delay intervals were 1 week, 1 month, 4 months, 1 year, 3
years, and 9 years. The immediate reward amounts were $999, $995, $990, $960, $940, $920,
$850, $800, $750, $700, $650, $600, $550, $500, $450, $400, $350, $300, $250, $200, $150,
$100, $80, $60, $40, $20, $10, $5, and $1. To minimize the motoric demands of the task, all
participants indicated their choice orally by saying "now" to choose the immediate option or
"later" to choose the delayed option. The examiner recorded their responses by pressing one
of two designated keys on a keyboard. Trials were not timed. Over the course of the
experiment, each participant received all combinations of immediate rewards and delays
presented above in a randomized order (174 trials total).
3.2.3 Genotyping
Genotyping was carried out according to the protocol described in Chapter 2. In our sample,
24, 72, and 32 patients fell in the COMT Val/Val, Val/Met, and Met/Met groups, respectively.
The DRD2 C957T break down was 21 C/C, 65 C/T, and 42 T/T. These distributions did not
depart from the Hardy-Weinberg equilibrium (COMT: x2 = 2.144, df = 1, p = 0.143; DRD2: (2
0.245, df = 1, p = 0.621). Because only 9 and 12 participants fell in the D4 .7+ and DRD3 C/C
groups, respectively, we excluded DRD3 and DRD4 from further analysis.
3.2.4 Statistical analysis
The principal dependent variable was the discounting rate. We used the following approach to
estimate the discounting rate for each participant: First, we estimated the present value (PV) of
1000
all delayed rewards using a hyperbolic discounting function, PV = ,000 where "k" is the
1+k-D'
discounting rate, and "D" is delay to reward in weeks. For each trial, we used the present
values of the selected (PV,,,ected) and rejected (PVeected) choices to calculate the probability of
the selected item: p = **'a*'* , where "a" is a positive constant. Next, we used
PVselected r PVrejected
an optimization routine to find values of "a" and "k" that minimized the sum of logarithms of
probabilities over all trials during the experiment. Because discounting rate "k" is not normally
distributed, we applied a logarithmic transform before further analysis to normalize "k". A
univariate analysis of covariance (ANCOVA) compared the logarithm of the discounting rates
among different genotypes. We included age and sex in the ANCOVA as covariates because
previous research uncovered age and sex differences in cognitive control ability19 2,193 and COMT
enzyme activity.73 We also included LEDD, disease duration, and H&Y stage as covariates in the
model to control for differences in dopamine replacement dosage and the severity of motor
symptoms among participants. We followed significant results with post-hoc tests. All data
were analyzed using MATLAB 2009a (MathWorks Inc., Natick, MA) and SPSS 11.5 (SPSS Inc.,
Chicago, IL).
3.3 Results
Participants were well matched in terms of age, sex, PD duration, H&Y stage, LEDD, number on
agonists, MMSE, BDI, and education across COMT genotypes (Table 3.2). A significantly larger
number of DRD2 C/C individuals were taking dopamine agonists compared to C/T and T/T
carriers (z2 = 6.546, df = 2, p = 0.038). In addition, DRD2 C/T carriers were significantly older
than C/C carriers (C/C: M = 63.4, SD = 8.7; C/T: M = 68.6, SD = 8.2; p = 0.049). This age
difference was taken into account by including age a covariate in all analyses. Patients were
well matched on all other characteristics across DRD2 genotypes (Table 3.3).
The probability of choosing the delayed reward decreased as the amount of the immediate
reward, or latency of the delayed reward, increased for both COMT and DRD2 genotypes
(Figure 3.1). This result indicated that participants attended to manipulations of reward and
delay during the experiment.
The subjective value of the delayed $1000 decreased for all genotypes as delay to the reward
increased (Figure 3.2). The discounting rates for COMT and DRD2 genotypes are presented in
Figures 3.3. To examine the effect of variation of each gene of interest on reward impulsivity,
we used a univariate ANCOVA with the logarithm of the discounting rates as the dependent
variable and genotype as the independent factor. Age, sex, disease duration, total LEDD, and
H&Y stage were covariates in the ANCOVA. The main effect of COMT on the discounting rate
was not significant (F2,120 = 0.885, p = 0.415), but the main effect of DRD2 was significant (F2,120
= 3.313, p = 0.040, i12= 5.23%). Planned post-hoc t tests revealed that C/T and T/T carriers had
significantly higher discounting rates compared to C/C carriers (C/C: M = -5.2, SD = 1.3; C/T: M =
-4.1, SD = 1.6; T/T: M = -4.3, SD = 1.7; C/C vs. C/T: p = 0.006 one-sided; C/C vs. T/T: p = 0.042
one-sided).
3.4 Discussion
The goal of this study was to examine whether select polymorphisms that putatively result in
increased dopamine signaling reduce the ability to delay gratification in PD patients receiving
dopamine replacement therapy. Consistent with our hypothesis, we found that PD patients
with at least one T allele of DRD2 C957T had significantly increased discounting rates relative to
C/C carriers. Contrary to our hypothesis, COMT Val158Met variation did not alter behavioral
scores.
Impact of D2 variation on delay of gratification
D2 receptors are densely expressed in the ventral striatum and amygdala, 27 131 which are two
nodes of the delay of gratification network.22 ' 231 232 Functional MRI studies in humans showed
that the ventral striatum tracked the subjective value of delayed rewards,237 and lesions of
ventral striatum in rats resulted in reduced ability to delay gratification. 225,231,232 Increased D2-
dependednt signaling in these areas may adversely impact their function, resulting in a reduced
ability to delay gratification. These regions are interconnected with the OFC.19 Given the
importance of OFC in delay of gratification, 237,238 it is also possible that altered activity in the
OFC caused the observed results.
No effect of COMT Cal158Met polymorphism on delay of gratification
The negative COMT finding was unexpected and demands further explanation. COMT has not
been extensively studied in delay discounting tasks. One study showed that healthy adults and
abstinent alcoholics with at least one Met allele were significantly less impulsive than Val/Val
homozygotes on a discounting task with hypothetical monetary rewards. 66 A second study,
however, showed that the Met/Met homozygote ADHD adolescents on drug holiday and
controls had increased discounting rates relative to carriers of at least one Val allele.262 These
authors did not carry out post hoc tests, but examination of the means and standard deviations
in their paper reveled that the significant main effect of COMT was likely due the ADHD group
alone. Some reasons for the discrepancy between the two studies may be differences in
disease status, participant ages, and small sample sizes. Importantly, the authors of the second
study told their participants prior to the experiment that one reward amount, randomly
selected, would be given to the participant at the end of the experiment, regardless of the
choice delay. This instruction effectively voided the delay to reward manipulation and
complicated the interpretation of their finding. Nonetheless, both studies suggested that
COMT plays a role in delay of gratification decisions.
A possible explanation emerged from a study that examined delay discounting in healthy young
adults taking low doses of levodopa (a Madopar pill containing 150mg levodopa).239 Although
all participants in the study showed decreased delay discounting on levodopa, the magnitude of
the change in discounting was much greater for some than others. The authors found that the
level of increase in discounting of future rewards on levodopa, relative to baseline, was
significantly correlated with bilateral BOLD signal in the amygdala. Thus, individual
susceptibility to medication-induced delay aversion may depend on the amygdala, where D2
receptors are densely expressed.127-131 COMT is critical for dopamine clearance in the PFC. 78
Thus, our finding that DRD2, but not COMT, variation altered discounting behavior is consistent
with the finding that amygdala activity was correlated with medication-induced changes in
delay of gratification judgments.
DRD3 and DRD4
Most dopaminergic agonists have a high affinity for D4 receptors,2 63 and the interaction
between DRD2 and DRD4 modulates ability to delay gratification.58 DRD3 variation may also be
important in determining cognitive response to dopamine replacement therapy, but we did not
have enough participants to analyze the impact of DRD3 and DRD4 polymorphisms. Most
dopamine agonists have a high affinity for D3 receptors,80,200 and D3 receptors are densely
expressed in the ventral striatum and limbic cortex and strategically located to modify functions
carried by the limbic loop. 127,137,138,199 Further, repeated administration of levodopa in animal
models of PD resulted in overexpression and ectopic expression of D3 receptors in the nucleus
accumbens and striatum, respectively.2 14 Voon et al's report that pramipexole, which has a 5-
10 fold higher selectivity for D3 than D2 receptors, 200 decreased delay of gratification in PD
patients with impulse control disorders further highlights the importance of elucidating the
impact of D3 variation in response to dopaminergic medication.
Conclusions
The present study adds to a growing body of literature that highlights the interaction between
variations in genes of the dopamine system and cognitive response to medication in PD.
Specifically, we showed that carrying the T allele of the DRD2 C957T polymorphism was linked
with more impulsive choices, and thus this allele may be a risk factor for behavioral impulsivity
in PD patients taking dopamine replacement therapy.
Characteristics of PD patients who completed the delay discounting task
Variable
No. of participants
Age (yrs)
PD duration (yrs)
Stage 1
H&Y Stage 2
Stage 3
LEDD (mg/day)
% taking agonists
PD patients
128 (82M; 46F)
66.6 (8.7)
5.6 (3.9)
17
102
9
615.3 (440.0)
56.3%
MMSE 28.2 (1.3)
BDI 6.3 (4.1)
Education (yrs) 16.6 (2.8)
Results are presented as mean (SD), number, or percentage.
Table 3.1
Table 3.2 Characteristics of COMT subgroups in delay discounting task
Variable COMT
Val/Val Val/Me
No. of participants 24 72
Age (yrs) 69.6 (6.7) 65.8 (8.
Sex M:F 14:10 44:28
PD duration (yrs) 5.2 (4.1) 5.2 (3.8
Stage 1 2 9
H&Y Stage 2 20 58
Stage 3 2 5
LEDD (mg/day) 569.7 (384.0) 594.5 (42
% taking agonists 54.2% 58.3%
MMSE 27.7 (1.5) 28.3 (1.
BDI 6.3 (3.6) 6.1 (4.1
Education (yrs) 16.5 (3.2) 16.7 (3.
§ ANOVA; Y Chi square test; E Fisher's exact test.
Results are presented as mean (SD), number, or percentage.
t
5)
7.0)
3)
0)
Met/Met
32
66.4 (10.0)
24:8
6.8 (3.8)
6
24
2
696.4 (506.7)
53.1%
28.2 (1.3)
6.5 (4.5)
16.5 (2.3)
p Value
0.175 §
0.320
0.135 §
0.839 E
0.475 §
0.862
0.251 §
0.918 §
0.967 §
Table 3.3 Characteristics of DRD2 subgroups in delay discounting task
Variable DRD2 p Value
C/C C/T T/T
No. of participants 21 65 42
Age (yrs) 63.4 (8.7) 68.6 (8.2) 65.3 (8.9) 0.027
Sex M:F 14:7 44:21 24:18 0.520
PD duration (yrs) 5.5 (3.3) 5.7 (4.1) 5.3 (3.8) 0.858
Stage 1 6 7 4
H&Y Stage 2 15 53 34 0.208 E
Stage 3 0 5 4
LEDD (mg/day) 616.4 (325.1) 591.6 (453.6) 651.5 (474.0) 0.792 §
% taking agonists 81.0% 49.2% 54.8% 0.038
MMSE 28.5 (1.2) 28.3 (1.3) 27.8 (1.3) 0.065 §
BDI 6.1 (3.4) 5.9 (4.2) 7.0 (4.2) 0.400 §
Education (yrs) 17.2 (2.3) 16.8 (3.0) 16.1 (2.8) 0.274 §
§ ANOVA; Y Chi square test; E Fisher's exact test.
Results are presented as mean (SD), number, or percentage.
Significant results are indicated in bold font.
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Figure 3.1 Probability of choosing the delayed reward
Probability of choosing the delayed reward as a function of the magnitude of the
immediate reward and latency of the delayed reward. Probability of choosing
the delayed reward decreased as the amount of the immediate reward increased
for A) COMT, and B) DRD2 genotypes. Probability of choosing the delayed
reward decreased as the latency of the delayed reward increased for C) COMT,
and D) DRD2 genotypes. Error bars depict SEM. Abbreviations: M: methionine;
V: valine.
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Figure 3.2 Discounting curves as a function of COMT and DRD2 genotypes
Subjective value of $1,000 after delays ranging from 1 week to 9 years.
Discounting functions broken down by A) COMT Val158Met, and B) DRD2 C957T
genotypes.
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Figure 3.3 Log-transformed discounting rates as a function of COMT and DRD2 genotypes
Smaller negative numbers reflect more reward impulsivity. A) We found no
difference in discounting rates among the COMT genotypes. B) C/T and T/T
carriers had significantly larger discounting rates compared to C/C carriers. Error
bars depict SEM. * p = 0.006 one-sided; # p = 0.042 one-sided.
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4 Reflection impulsivity
4.1 Introduction
Reflection impulsivity measures the tendency to gather and evaluate information before
making a decision. 265 This often neglected dimension of impulsivity has traditionally been
studied using the Matching Familiar Figures Test (MFFT), introduced by Kagan (1964).266-268 In
this task, participants view a line drawing of a familiar object (the standard) and 4, 6, or 8 probe
267 hmi dnia otesadrpictures, presented below the standard picture. One of them is identical to the standard
while others contain slight variations in one or more features. The participants' task is to
choose the probe that is identical to the standard. The critical variables are the latency of the
first choice and number of errors until the correct choice is made, averaged over 12 or 20
trials.267,268 Using the median latency of the first response and median number of errors, Kagan
divided participants into four groups: Those with below median error rates and above median
first-response latency were termed "reflective", whereas fast-inaccurate participants were
considered "impulsive". 267 The other two groups, fast-accurate and slow-inaccurate, which
269
constituted about a third of the participants, have received little attention. Using this task,
other researchers have identified several groups as reflection impulsive: children with ADHD,269-
271 current and past cigarette smokers, 272 current and past ecstasy (3,4-methylenedioxy-
methamphetamine) users,273 -27 detoxified alchoholics,276 and pathological gamblers.
Some investigators have argued that the MFFT does not provide a pure measure of reflection
impulsivity because it relies on latency measures, has low error rate reliability, and puts an
undue burden on visual search and working memory capacities.22-28 To overcome these
shortcomings, another laboratory introduced the Information Sampling Task in 2006.280 This
task has a unitary measure of impulsivity, unlike the MFFT speed-accuracy composite score, and
does not overly tax visual processing or working memory.280 On each trial, participants explore
a grid of 25 boxes that hides an underlying arrangement of two colors. Participants choose how
much information they want to sample from the grid before deciding which of the two colors is
in the majority among the 25 boxes. Because the explored areas remain visible during a trial,
the task has a negligible working memory load. The extent of exploration before making a
judgment provides an index of a participant's reflection impulsivity. Critically, fast-inaccurate
responders on MFFT open significantly fewer boxes on the Information Sampling Task than
slow-accurate responders, indicating that the task can successfully identify those who have
traditionally been identified as reflection impulsive based on the MFFT double-median split.
Similar to MFFT studies of individuals with impulse control problems, investigators have shown
that alcohol-dependent individuals, problem gamblers, 281 and amphetamine, opiate,280 and
cannabis users282 sample significantly less information than matched controls. 28 1
4.1.1 Neural substrates of reflection impulsivity
Only one study has examined the neural substrates of reflection impulsivity. The investigators
administered MFFT to a group of controls and individuals with OFC and non-OFC (primarily
dorsolateral PFC) damage. 283 ,28 4 OFC-lesioned individuals had more errors and shorter first-
response latencies relative to controls, whereas those with non-OFC damage only had more
errors.283,284 This finding suggests that OFC plays a role in mediating reflection impulsivity. OFC
receives dopaminergic inputs primarily from the VTA, which is relatively preserved in the early
stages of PD. As a result, dopamine replacement therapy may cause a dopamine overdose in
the OFC, resulting in reflection impulsivity.
4.1.2 Pharmacology and genetics of reflection impulsivity
The strongest evidence for a dopaminergic role in reflection impulsivity comes from studies of
children diagnosed with ADHD. Reflection impulsivity is common in ADHD 269-271 and drugs that
increase dopamine signaling-methylphenidate and amphetamine-significantly improve MFFT
performance in these children.28 s287
Investigators have also shown that bupropion, a selective dopamine and norepinephrine
reuptake inhibitor,288 was as effective as methylphenidate in reducing reflection impulsivity in
children with ADHD. 289 Low doses of pramipexole-a dopamine agonist commonly used in
PD-also reduced reflection impulsivity in controls who performed the Information Sampling
Task.290
Only one study has examined reflection impulsivity in children with ADHD using the Information
Sampling Task. The investigators administered this task to unmedicated and medicated (0.5
mg/Kg methylphenidate) children with ADHD, and age- and education-matched controls. The
researchers found that unmedicated ADHD children opened the same number of boxes as
controls but made significantly more poor decisions (i.e., they often chose the minority
color).29 ' Using parametric tests, the authors did not find a difference in the performance of
medicated and unmedicated children with ADHD and concluded that methylphenidate did not
alter this dimension of impulsivity in ADHD. Examination of Figure 1A in their paper, however,
revealed that the interquartile range of the "Total Poor Decisions on [Information Sampling
Task]" for methylphenidate-treated children had a large overlap with that of controls, whereas
the interquartile range of the placebo group had no overlap with controls. It is likely, therefore,
that only a subgroup of the ADHD children showed improved performance on the Information
Sampling Task when taking methylphenidate. Indeed, methylphenidate response in ADHD
follows and inverted-U dopamine response curve: Children with the 7-repeat allele of DRD4-
which reduces dopamine signaling-required higher doses of methylphenidate to reduce
impulsivity and hyperactivity symptoms65 and carriers of COMT Val allele were more likely to
benefit from medication than Met carriers.292 It is probable, therefore, that only children with
reduced dopamine signaling improved in performing the Information Sampling Task when
taking methylphenidate.
It is unclear whether serotonin plays a role in reflection impulsivity. Some investigators argued
that because ecstasy is neurotoxic to serotonin (and to a lesser extent to dopamine) cells,
increased reflection impulsivity-shorter response latencies and more errors on the MMFT2
27s-in ecstasy users, compared to controls, indicates that serotonin modulates reflection
impulsivity. This view is not accepted universally, however, because other investigators
reported similar performance between ecstasy users and controls on the Information Sampling
Task.2 82
Accumulating evidence shows that dopamine gene polymorphisms impact reflection
impulsivity. Researchers showed that drug-naive children diagnosed with ADHD who had the 7-
repeat allele of DRD4 were significantly more impulsive on the MFFT than children who did not
carry the allele.64 These children made significantly more errors and had significantly shorter
64thresponse times. Critically, the two groups did not differ in response inhibition, measured by
the Stop Signal Task, indicating that differences in MFFT response latencies were not due simply
to reduced motor inhibition. Another laboratory found a significant effect of variation in the
dopamine beta hydroxylase gene-which encodes the protein that converts dopamine to
norepinephrine-on MFFT performance in non-drug-naive ADHD patients, though researchers
could not reproduce the DRD4 result.293 In summary, although in their infancy, genetic studies
suggest that variation in genes of the dopamine system alters reflection impulsivity.
4.1.3 Hypothesis
A lesion study in humans has linked evidence gathering to OFC function.283 This area is
susceptible to dopamine overdose in PD because dopaminergic inputs to the orbitomedial PFC
24are relatively spared, at least in the early stages of the disease. Genetic studies showed that
increasing dopaminergic signaling in children with ADHD-who putatively have low baseline
levels of dopamine2 94 -iMproved their performance on measures of reflection impulsivity.64
Because of dopamine overdose, we hypothesized that this pattern would be reversed in PD:
Patients who carry candidate alleles that increase dopamine signaling would show a reduced
tendency to gather and evaluate evidence before making a decision while taking dopamine
replacement therapy, compared to non-carriers. We addressed four specific questions: (1) Do
COMT Met/Met and Val/Met carriers sample less information than Val/Val carriers?, (2) Do
DRD2 T/T and C/T carriers sample less information than C/C carriers?, (3) Do DRD3 Gly/Gly
carriers sample less information than Ser/Gly and Ser/Ser carriers?, and (4) Do D4.7- carriers
sample less information than D4.7+ carriers? We predicated that individuals with the risk
variants of COMT (Met allele), DRD2 (T allele), DRD3 (Gly allele), and DRD4 (absence of 7-repeat
allele) would open fewer boxes in the Information Sampling Task, indicating increased
reflection impulsivity due to dopamine overdose.
4.2 Materials and methods
4.2.1 Participants
We recruited 130 PD patients who satisfied the inclusion and exclusion criteria described in
chapter 2 (Table 4.1). The self-identified racial and ethnic distribution of participants was: 127
White / not Hispanic or Latino, 2 White / Hispanic or Latino, and 1 Asian.
4.2.2 Experimental design
We adapted the Information Sampling Task.29 s Participants viewed a 5x5 matrix of gray boxes
that hid an underlying arrangement of two colors (Figure 4.1). On each trial, the two colors
were selected randomly by the computer on each trial and could be blue, cyan, green,
magenta, red, or yellow, with the arrangement and proportion of boxes in each color changing
from trial to trial. Each gray box had a number (1 to 25). To limit the motor demands of the
tasks, participants called the number on the gray box they wanted to open, and the
experimenter clicked the gray box to reveal the underlying color to the participants. Once
clicked, the boxes remained visible during the remainder of the trial to minimize the memory
requirements of the task. Participants uncovered as many gray boxes as they desired at their
own rate. When they were ready to decide which of the two underlying colors was in the
majority among the total array of boxes, they indicated their choice orally and the
experimenter recorded their response by clicking one of the two dedicated boxes at the bottom
of the screen. Participants received feedback on whether their choice was correct or incorrect.
A correct choice earned them 100 points, while an incorrect choice resulted in a loss of 100
points. We asked the participants to maximize the number of points they earned during the
experiment. If participants completed a trial in less than 30 sec, they had wait for the
remainder of the 30 sec before the next trial started. This minimum trial-to-trial wait period
was programmed into the experiment to deter participants from answering quickly to finish the
task. Participants completed one practice trial before starting the experiment. During the
experiment, they completed two trials for each of the following color proportions: 13:12, 14:11,
15:10, and 16:9 (total of 8 trials).
4.2.3 Genotyping
Genotyping was carried out according to the protocol described in Chapter 2. In our sample,
26, 72, and 32 patients fell in the COMT Val/Val, Val/Met, and Met/Met groups, respectively.
The DRD2 C957T break down was 21 C/C, 66 C/T, and 43 T/T. These distributions did not
depart from the Hardy-Weinberg equilibrium (COMT: , = 1.575, df = 1, p = 0.210; DRD2: 2 =
0.267, df = 1, p = 0.605). Because only 9 and 13 participants fell in the D4.7+ and DRD3 C/C
groups, respectively, we excluded DRD3 and DRD4 from further analysis.
4.2.4 Statistical analysis
The principal dependent variable was the average number of boxes that a participant opened
before making their decision. A univariate analysis of covariance (ANCOVA) compared the
mean number of opened boxes among different genotypes. Because previous research
uncovered age and sex differences in cognitive control ability19 2,193 and COMT enzyme
activity,73 we included age and sex in the ANCOVA as covariates. We also included LEDD,
disease duration, and H&Y stage as covariates in the model to control for differences in
dopamine replacement dosage and the severity of motor symptoms among participants.
Because the number of earned points and accuracy convey the same information, we only
analyzed accuracy using an ANCOVA with age, sex, disease duration, H&Y stage, and LEDD as
covariates. When ANCOVAs were significant, we conducted post-hoc tests. All data were
analyzed using MATLAB 2009a (MathWorks Inc., Natick, MA) and SPSS 11.5 (SPSS Inc., Chicago,
IL).
4.3 Results
Participants were well matched in terms of age, sex, PD duration, H&Y stage, LEDD, number on
agonists, MMSE, BDI, and education across COMT genotypes (Table 4.2). A significantly larger
number of DRD2 C/C individuals were taking dopamine agonists as compared to C/T and T/T
carriers (, 2 = 7.450, df = 2, p = 0.024). Further, DRD2 C/T carriers were significantly older than
C/C carriers (C/C: M = 63.4, SD = 8.7; C/T: M = 68.5, SD = 8.1; p = 0.051). This age difference
was taken into account by including age a covariate in all analyses. Patients were well matched
on all other characteristics across DRD2 genotypes (Table 4.3).
To examine the effect of variation in each gene on reflection impulsivity (Figure 4.2), we used a
univariate ANCOVA with average number of opened boxes as the dependent variable and
genotype as the independent factor. Age, sex, disease duration, total LEDD, and H&Y stage
were covariates in the ANCOVA. The main effect of COMT on the number of opened boxes was
not significant (F2,122 = 2.507, p = 0.086), but the main effect of DRD2 was significant (F2,122 =
3.794, p = 0.025, i 2 = 5.86%). Planned post-hoc comparisons revealed that T/T carriers opened
significantly fewer boxes than C/C carriers before making a decision, while C/T and C/C
subgroups were similar (C/C: M = 12.6, SD = 4.5; C/T: M = 12.8, SD = 5.3; T/T: M = 10.5, SD = 3.6;
C/C vs. T/T: p = 0.050 one-sided; C/T vs. C/C: p = 0.362 one-sided). Accuracy did not differ
among the COMT (Val/Val: M = 96.6%, SD = 9.1%; Val/Met: M = 96.9%, SD = 7.2%; Met/Met: M
= 96.1, SD = 8.1%; p = 0.826) and the DRD2 (C/C: M = 97.6%, SD = 5.0%; C/T: M = 97.0%, SD =
7.9%; T/T: M = 95.6%, SD = 8.6%; p = 0.596 ) genotypes.
4.4 Discussion
This experiment tested the hypothesis that pharmacogenetic elevation of dopaminergic
signaling in PD patients would increase reflection impulsivity. Consistent with our hypothesis,
the results showed that medicated PD patients with the DRD2 T/T genotype were significantly
more reflection impulsive than C/C carries, but C/C and C/T carriers showed similar
performance.
Impact of D2 variation on reflection impulsivity
A lesion study in humans showed that reflection impulsivity is linked with OFC function.283 D2
receptors are densely expressed in limbic structures, such as amygdala, 127131 that have strong
connections with the OFC. 22 Therefore, excessive D2 signaling may indirectly impair OFC
function, causing increased reflection impulsivity.
COMT variation did not influence reflection impulsivity
We did not find a main effect of the COMTVal158Met polymorphism on reflection impulsivity.
Reports of an association between COMT variation and cognition are primarily from tasks that
have heavy executive demands, such as the Wisconsin Card Sorting Test 90,29 6 and the n-Back
task.90 The Wisconsin Card Sorting Test297 uses a set of cards containing geometric figures.
Participants learn-by trial and error-to sort the cards according to a rule (color, form, or
number). Then, without a warning, this rule changes and they must learn to sort the cards
according to a new rule. Therefore, stable maintenance of a rule while it is relevant-a task
that heavily depends on PFC function 298 -is a critical requirement for successful completion of
the task. In the n-Back task,299 participants must maintain and monitor a sequence of stimuli in
working memory, and respond when a stimulus is identical to one presented n-trials back.
Because of its maintenance and monitoring feature, this task, similar to the WCST, relies heavily
on working memory and the PFC. The lack of a COMT effect in this study could be due to the
low executive demands of the Information Sampling Task. Specifically, because the explored
boxes remained visible during the trial, participants had immediate access to all the information
they needed to make a decision. Importantly, they did not need to maintain the ratio of the
explored colors in memory because this information was on the computer screen in front of
them.
COMT and DRD2 interaction on reflection impulsivity
It is possible that COMT exerted an influence in this experiment through an interaction with
DRD2. To examine this hypothesis directly, we combined the C/T and C/C genotypes of the
DRD2 C957T polymorphism and then ran an ANCOVA with COMT (Val/Val vs. Val/Met vs.
Met/Met) and DRD2 (T/T vs. C/T & C/C) as the independent factors. Age, sex, disease duration,
total LEDD, and H&Y stage were covariates in this model. Similar to our previous analysis, the
main effect of DRD2 was significant (F1,119 = 10.410, p = 0.002, i12 = 8.04%) and the main effect
of COMT was not (F2,119 = 1.768, p = 0.175). Critically, the new analysis uncovered a significant
interaction between COMT and DRD2 (F2,119 = 3.323, p = 0.039, r12 = 5.29%). Carriers of the
COMT Met/Met genotype opened more boxes (i.e., they were not reflection impulsive) but only
when they did not carry the DRD2 T/T genotype (Figure 4.3). DRD2 T/T homozygotes showed
increased impulsivity, independent of the number of COMT Met alleles they carried.
The interaction between COMTVaI158Met and ANKK1 Taqia follows the inverted-U dopamine
response curve. Investigators showed that Met/Met carriers performed better than Val carriers
on the Stroop Task in the presence of at least one Al allele-which results in a 30 to 40%
reduction in the density of striatal D2 receptors.300 In the absence of the Al allele, however,
Met/Met carriers performed worse than Val carriers. The researchers also measured prolactin
levels in their participants. Because prolactin is inhibited by dopamine, levels of this protein
provided an indirect measure of dopamine levels. They showed that prolactin levels were low
in the Met/Met individuals who did not carry Al (the Al- group) but were high in Met/Met and
Al carriers. This result indicated that too much dopamine in the Met/Met and Al- carriers
resulted in impaired performance, whereas optimal dopamine levels in the Met/Met and Al
carriers allowed for best performance.
Our finding that Met/Met carriers who did not have the DRD2 T/T genotype had the least
reflection impulsivity is consistent with the above report and the inverted-U dopamine
response curve. Because DRD2 C957T and ANKK1 Taqla are in strong linkage disequilibrium (d'
= 0.832 to 1, indicating near complete dependence),132 ,134 the Al group in the above study likely
corresponded to our C/C-C/T group. Met/Met carriers in the Al group had the highest
prolactin levels among all COMT and ANKK1 genotype combinations in another study,301
indicating that the Met/Met and A1+ combination is associated with reduced dopamine levels.
It is not surprising, therefore, that the Met/Met carriers in the C/C-C/T group had the best
performance in our study: These individuals likely had the lowest levels of baseline dopamine,
and thus did not experience a dopamine overdose while taking dopamine replacement therapy.
Conclusions
We showed that the DRD2 T/T homozygotes-who putatively have increased D2 receptor
density in the striatum and increased D2 affinity for dopamine-had greater reflection
impulsivity than C/C carriers. We also showed a significant interaction between COMT and
DRD2, whereby individuals with the lowest amounts of baseline dopamine performed better
than all other groups while taking dopamine replacement therapy
Characteristics of PD patients who completed the Information Sampling Task
Variable PD patients
No. of participants 130 (84M; 46F)
Age (yrs) 66.5 (8.7)
PD duration (yrs) 5.5 (3.8)
Stage 1 17
H&Y Stage 2 103
Stage 3 10
LEDD (mg/day) 617.2 (435.0)
% taking agonists 55.4%
MMSE 28.2 (1.3)
BDI 6.2(4.1)
Education (yrs) 16.7 (2.8)
Results are presented as mean (SD), number, or percentage.
Table 4.1
Characteristics of COMT subgroups in Information Sampling Task
Variable COM~
Val/Val Val/M
No. of participants 26 72
Age (yrs) 68.8 (7.1) 65.8 (8.
Sex M:F 15:11 45:27
PD duration (yrs) 5.3 (4.1) 5.1 (3.
Stage 1 2 9
H&Y Stage 2 21 58
Stage 3 3 5
LEDD (mg/day) 583.6 (371.6) 594.1 (42
% taking agonists 53.8% 56.9%
MMSE 27.8 (1.4) 28.2 (1.
BDI 6.1(3.5) 6.1(4.
Education (yrs) 16.7 (3.2) 16.7 (3.
§ ANOVA; Y Chi square test; f Fisher's exact test.
Results are presented as mean (SD), number, or percentage.
r
et
5)
7)
3.0)
3)
2)
0)
p Value
0.338 3
0.334w
0.115 §
Met/Met
32
66.4 (10.0)
24:8
6.8 (3.8)
6
24
2
695.4 (506.7)
53.1%
28.2 (1.3)
6.5 (4.5)
16.5 (2.3)
0.496
0.922"
0.323 §
0.890 §
0.962 §
Table 4.2
Characteristics of DRD2 subgroups in Information Sampling Task
Variable DRD2 p Value
C/C C/T T/T
No. of participants 21 66 43
Age (yrs) 63.4 (8.7) 68.5 (8.1) 65.1 (8.9) 0.024 §
Sex M:F 14:7 45:21 25:18 0.550
PD duration (yrs) 5.5 (3.3) 5.7 (4.1) 5.3 (3.8) 0.840 §
Stage 1 6 7 4
H&Y Stage 2 15 53 35 0.196 £
Stage 3 0 6 4
LEDD (mg/day) 616.4 (325.1) 593.6 (446.9) 653.8 (468.6) 0.782 §
% taking agonists 81.0% 47.0% 55.8% 0.024
MMSE 28.5 (1.2) 28.3 (1.3) 27.8 (1.3) 0.082 §
BDI 6.1 (3.4) 5.8 (4.3) 6.9 (4.2) 0.388 §
Education (yrs) 17.2 (2.3) 16.8 (3.0) 16.2 (2.9) 0.362 §
§ ANOVA; X Chi square test; E Fisher's exact test.
Results are presented as mean (SD), number, or percentage.
Significant results are in bold font.
Table 4.3
Figure 4.1 Information Sampling Task
In this example, a participant has revealed boxes 1, 7, 13, 15, 17, and 24 before
deciding whether the green or the yellow boxes are in the majority.
AJdZ0
0
z
CoMT
15
14.
13-
12.
11.
10.
9
n 26
VN
I
72
V/M
B
I
DRD2
14.
13
12.
11.
10.
9
n32
M/M
*
I
21
C/C
I
66
C/T
43
T/T
Figure 4.2 Number of explored boxes as a function of COMT and DRD2 genotypes
COMT did not have a direct effect on reflection impulsivity (A), while the T/T
genotype of DRD2 C957T polymorphism resulted in increased reflection
impulsivity (B). Error bars depict SEM. * p = 0.05.
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Figure 4.3 Interaction between COMT and DRD2 in the Information Sampling Task
DRD2 T/T homozygotes were reflection impulsive, independent of the number of
COMT Met alleles. COMT Met/Met genotype resulted in decreased reflection
impulsivity, but only in participants who did not carry the DRD2 T/T genotype.
5 Hallucinations
5.1 Introduction
Hallucinations are a common occurrence in PD and typically start several years after disease
onset. Cross-sectional studies indicate that roughly a third of non-demented patients on
chronic dopamine replacement therapy experience hallucinations, while longitudinal studies
reveal that up to 75% of patients develop hallucinations over a 20-year period.302 The
prevalence of hallucination in PD patients with dementia is over 50%,303 but hallucinations in
that context are beyond the scope of this chapter. Our focus is on hallucinations that occur in
the context of dopamine replacement therapy in patients who retained insight into the nature
of their hallucinations and were awake and alert, with eyes open, when the unusual
experiences occurred.
The most prevalent forms of hallucinations in PD are visual, auditory, and benign. Typical visual
hallucinations consist of seeing a few people, animals, or objects, in color or black-and-white,
and stationary or moving. 43 Patients are often external observers of the scene and at first
cannot distinguish whether the images are real or imaginary, but, in the absence of dementia,
they eventually realize that the hallucinations are unreal. 4 3,304 Hallucinations disappear in
seconds to minutes on their own or after patients try to interact with them or touch them.43
Visual hallucinations may occur during the day or night but are more frequent in low-light
conditions. 43 Early in the disease, they are neutral or friendly, but later on insects, rats, worms,
304,305and snakes may appear. Auditory hallucinations may accompany visual hallucinations,
where they provide the soundtrack, or they may occur independently as ringing and knocking
sounds, or as music. 4 3 Auditory hallucinations in PD, unlike schizophrenia, are neutral and non-
threatening.43 Patients may also experience benign hallucinatory experiences, such as sensing a
presence, briefly seeing a person or animal passing in their peripheral visual field, or seeing an
inanimate object as animate, such as a tree branch as a cat.43 Risk factors for hallucinations
include dopamine replacement therapy, advanced age, coexistent depression, dementia, and
dementia.306
5.1.1 Neural substrates of hallucinations
The pathogenesis of hallucinations in PD is unclear, although lines of evidence suggest that
impaired visual processing plays a role in the development of visual hallucinations. First,
investigators found that visual acuity-measured using an Snellen chart 307 or Landolt Cs at a
distance of 5 meters308-was worse in patients with visual hallucinations relative to controls.
Second, researchers reported that visual hallucinations disappeared after cataract surgery in
two PD patients who had bilateral cataracts.309 Third, in the Charles Bonnet syndrome, visual
hallucinations develop secondary to visual loss (e.g., due to macular degeneration) in
cognitively intact older individuals.310'31' Similarities between hallucinations in PD and the
Charles Bonnet syndrome-retained insight, occurrence in evening or at night, awareness of
the unreal nature of complex hallucinationS30s,312suggest that disruptions in early visual
processing contribute to the development of hallucinations in PD as well. Nevertheless, visual
deficits are probably not the primary cause of hallucinations in PD because reducing dopamine
replacement therapy-which impairs visual processing in PD33,34-remedies hallucinations.
Few functional imaging (fMRI and PET) studies have examined the neural underpinnings of
hallucinations in PD.305,315-318 These experiments have yielded heterogeneous results because
1) they were carried out when patients were not hallucinating, and 2) each study used a
different cognitive task to assess cortical function (see 43 for review). Still, these reports, taken
together, suggest that patients with visual hallucinations have reduced cortical activity in
primary and secondary visual areas and increased activity in the PFC.30s,31 -318 Some
investigators have suggested that PFC dysfunction results in a lack of suppression of internally
generated thoughts and images, or the misinterpretation of internal representations as
external ones, thus causing hallucinations.31 ,31 1
5.1.2 History of hallucinations in pre- and postlevodopa eras
Prior to 1957, it was generally accepted that dopamine was simply a precursor for the
neurotransmitter noradrenalin.32 0 During this period, clinicians treated PD with anti-cholinergic
drugs-known to be hallucinogenic-antihistamines, and amphetamines.321 32 3 The beneficial
effects of the anticholinergics were probably due to their interaction with midbrain
dopaminergic cells because the SNpc and VTA receive dense cholinergic inputs-from the
pedunculopontine and laterodorsal tegmental nuclei-and cholinergic interneurons in the
striatum express D, and D2 receptors.324 32 Similarly, antihistamines likely lessened symptoms
because they have some anticholinergics effects.m
In a groundbreaking experiment, Arvid Carlsson and colleagues (1957) injected rabbits and rats
with reserpine, which depleted brain reserves of dopamine and noradrenalin. They showed
that subsequent levodopa administration increased brain levels of dopamine, but not
adrenaline, and reversed the reserpine-induced akinesia and sedation."'" 9 This result,
suggesting that dopamine is a putative neurotransmitter in the brain, violated accepted dogma
and, hence, was met with resistance.320 Still, Carlsson's discovery, together with reports of
reduced dopamine levels in the urine and brains of PD patients, suggested that increasing brain
levels of dopamine would have therapeutic effects.4
In 1961, the first dopamine replacement therapy trials were carried out in PD patients: Barbeau
and colleagues330 in Montreal and Birkmayer and Hornykiewicz 331 in Vienna reported short-
lived improvements in akinesia, rigidity, and tremor after administration of up to 200 mg of
DOPA. Between 1961 and 1967 numerous groups attempted to replicate and expand these
original reports. 3  Using oral and intravenous routes, investigators administered up to several
grams of DOPA variants alone, together with monoamine oxidase and DOPA decarboxylase
inhibitors-to reduce peripheral conversion of DOPA to dopamine-or with amphetamines.4
Although most studies found lessening of rigidity and akinesia, the transient nature of the
improvement and common reports of nausea, loss of appetite, and hypotension portended
330,332 laes1disaster for levodopa treatment. As late as 1965, prominent investigators believed that
the therapeutic results were placebo effects and recommended continuation of PD treatment
with anti-cholinergic and anti-histaminic drugs.321
In August of 1966, however, Cotzias and colleagues at the Brookhaven National Laboratory in
Long Island, New York, proved convincingly that DOPA could be used to treat PD symptoms in a
sustainable manner.333 These researchers used significantly larger doses than had been tried
previously. Their insight was to increase the medication dose gradually until patients showed
improvement or until side-effects set in. Patients tended to tolerate the medication well,
showing fewer side effects including vomiting, nausea, loss of appetite, and hypotension.
Cotzias et al. showed that 3 to 16 grams of dl-3,4-dihydroxyphenylalanine (a mix of D-DOPA and
L-DOPA) per day resulted in sustained improvement of symptoms in 8 of 16 patients. 333
Subsequently, they reported sustained improvement in 20 out of 28 patients.334 Soon, reports
appeared of hallucinations and psychiatric side effects in patients taking levodopa, particularly
in those with a past history of mental illness. This literature launched the debate about the
whether hallucinations are a part of the natural progression of PD.
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Fenelon and colleagues (2006) examined 1 9 th and 2 0 th century PD reports in English, French,
and German for documentation of hallucinations.338 They found that between the 1880s and
1940s investigators occasionally noted the presence of hallucinations, particularly in late-stage
patients with coexistent dementia, depression, or delirium.
A critical factor complicates the interpretation of these reports as evidence that hallucinations
are to be expected in PD pathophysiology: Dementia with Lewy bodies (DLB), the second most
common form of dementia after Alzheimer's disease,33 9 first entered the literature 1961 when
Okazaki et al. presented the case report of a patient with Lewy bodies, progressive dementia,
and quadriparesis. 3 40 DLB is characterized pathologically by the presence of cortical and
subcortical Lewy bodies and clinically identified by the presence of progressive disabling mental
impairment, fluctuating cognition, Parkinsonian symptoms (bradykinesia and cogwheel rigidity,
but rarely resting tremor), and visual hallucinations.3 41,3 42 Specifically, hallucinations are
present in up to 83% of DLB patients and occur early in the course of the disease.3433 44 Given
that DLB has only recently entered the clinical arena (DLB was not included in DSM-IV published
in 1994), it is likely that some of the early reports of hallucinations in PD patients with dementia
and delirium would be characterized as DLB today.338
The worldwide epidemic of von Economo encephalitis (encephalitis lethargica) from 1916 to
1927, a mysterious disease that killed about 23,000 people in the US alone, complicates the
interpretation of reports from the 1940s to the 1970s.34s,346 This disease, characterized by
encephalitis of the midbrain and basal ganglia with lymphocyte infiltration, resulted in
somnolence, lethargy, dyskinesias, hallucinations, delusions, and development of
Parkinsonism.347  Many patients who survived von Economo encephalitis developed
postencephalitic Parkinsonism (PEP), and by the 1930s, PEP accounted for roughly half of all
Parkinsonian cases.348 Despite their similar clinical presentations, PEP-induced Parkinsonism
differed from idiopathic PD on several dimensions: PEP patients did not present the classical
"pill-roll" tremor common in idiopathic PD; PEP could occur at any age, even childhood,
whereas PD typically occurs later in life; and unlike PD, which is characterized by cell loss in
SN/locus ceruleus and the presence of Lewy bodies, PEP brains showed "extensive and severe
bilateral diffuse degeneration and gliosis of substantia nigra and locus coeruleus in the absence
of Lewy bodies". 346
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Even with these differences, the vast number of PEP cases resulted in a false view that
idiopathic PD is synonymous with PEP, 346 and thus many authors did not distinguish between
idiopathic PD and PEP in their studies.338 Some even suggested that PD would "gradually
disappear" by the year 1980 as the PEP cohort aged.349 In this period, a handful of studies
focused exclusively on PD without a history of encephalitis and found few patients with
hallucinations (2 out of 194 in one report) 338 or none at all, 345 highlighting the rarity of
hallucinations in the absence of dopamine replacement therapy.
In summary, although hallucinations did occur in pre-levodopa days in about 5% of patients, 44
they occurred primarily in the context of confusional states, depression, dementia, delirium,
and anti-cholinergic medication use. Newer reports, documenting hallucinations in roughly
30% of patients, have focused primarily on hallucinations that occur with chronic dopaminergic
therapy, a clear sensorium, and absence of major depressive disorders.338 Using these criteria,
investigators showed that fewer than 2% of untreated patients experience hallucinations
(Aarsland et al.: n = 175; Shannon et al.: n = 164),35o,351 although one study with a small sample
352size (n = 30) reported a surprisingly large 27% hallucination rate among untreated patients.
Thus, it is possible that hallucinations are a natural component of PD progression, but their
occurrence is likely facilitated by dopaminergic medications.
5.1.3 Pharmacology and genetics of hallucinations
Several lines of evidence support the hypothesis that dopamine signaling is a central factor in
the development of hallucinations. 43,44,3s3,3s4 First, hallucinations are rare in PD patients who
are not taking dopaminergic medications. Second, drugs that increase dopamine signaling can
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induce or exacerbate hallucinations. Third, hallucinations can be treated successfully by
stopping or decreasing dopaminergic agents or by reducing dopamine signaling via dopamine
antagonists. In particular, investigators have shown that clozapine (a compound that blocks D1,
D2, D4, serotonin, ax-1 adrenergic, histamine, and muscarinic receptors), reduces psychotic
symptoms in 80% of PD patients,35 4 and that 76% of patients relapse after clozapine is
withdrawn .
Although anticholinergics can induce hallucinations in PD, these hallucinations lack the clear-
sensorium feature of dopaminergic-drug-induced hallucinations. Meta-analyses show that
dopamine agonists are two to five times more likely to induce hallucinations than levodopa
monotherapy or no therapy.356 ,357 Still, investigators have not been able to find a simple dose-
effect relationship between hallucinations and dopaminergic drugs. Mean daily levodopa dose,
LEDD, and duration of levodopa therapy are not significantly different between those with and
without hallucinations. 30 7,357 -360 Moreover, investigators showed that high, or sudden changes
in, plasma levels of levodopa may not be enough to induce hallucinations. 36' They delivered
intravenous levodopa to five patients with a history of recurrent hallucinations while they
stayed in a dim hospital room for two days. Although the patients had been experiencing
hallucinations for an average of three years, they did not experience hallucinations under these
experimental conditions. The small sample size and active hospital environment of the study,
however, complicate the interpretation of the results. Nonetheless, these results suggest a
complicated relation between amount of dopamine replacement therapy and onset of
hallucinations.
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A handful of studies that have examined the genetic basis of hallucinations in PD suggest that
the development of hallucinations may be linked with polymorphisms of genes that regulate
dopamine signaling. Makoff and colleagues (2000) examined the DRD3 Ser9Gly and DRD2 -
141C/del and ANKK1 Taq1A polymorphisms.10 2 They found that the A2/A2 genotype of Taq1A,
which results in increased D2 receptor density in the striatum, was disproportionately over-
represented in patients who developed hallucinations later in the disease. Goetz et al. (2001)
extended these results and showed that the Gly allele of the DRD3 Ser9Gly polymorphism,
which results in increased dopamine signaling, is associated with hallucinations. 362 Other
studies, however, have not been able to replicate these results. 363,3 6
4
5.1.4 Hypothesis
Neuroimaging studies suggest that hallucinations may be due to dysfunction of frontal cortical
areas, which have relatively spared dopaminergic input in the early stages of PD. It is possible,
therefore, that dopamine overdose may underlie the development of hallucinations in patients
with increased dopamine signaling who are taking dopamine replacement therapy. Thus, we
hypothesized that carriers of candidate alleles and genotypes that increase dopamine signaling
would be vulnerable to developing hallucinations due to disruption of activity in frontal cortical
networks that are spared from dopamine depletion early in the disease course.
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5.2 Materials and methods
5.2.1 Participants
We recruited 135 PD patients who satisfied the inclusion and exclusion criteria described in
chapter 2 (Table 5.1). The self-identified racial and ethnic distribution of participants was: 132
White / not Hispanic or Latino, 2 White / Hispanic or Latino, and 1 Asian.
5.2.2 Experimental and control groups
Patients were divided into three subgroups based on their answers to the Queen Square Visual
Hallucination Inventory.36s The benign subgroup consisted of 31 patients with benign, but not
formed, hallucinations. The formed subgroup included 35 patients with formed hallucinations.
All except 3 patients in this subgroup experienced benign hallucinations. Choosing a control
subgroup without formed and benign hallucinations is not a trivial matter because a patient
who has not developed hallucinations until the time of testing may develop hallucinations
afterward. To limit the possibility of including future hallucinators in the control set, we limited
this group to those patients who had had the disease for at least 5 years and had not
experienced any hallucinations. The control subgroup consisted of 26 PD patients.
5.2.3 Experimental design
We used the Queen Square Visual Hallucination Inventory to document the presence of formed
(visual or auditory) and benign (presence, passage, illusion) hallucinations at any time during
the course of the disease.36 s The following questions from the Queen Square Visual
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Hallucination Inventory examined presence, passage, and illusion hallucinations, respectively:
"Have you had the vivid sensation of the presence of somebody in the room with you, when in
fact there was no one there?", "Have you experienced a brief vision of movement past you, of
perhaps an animal or person, when in fact there was nothing there?", "Have you looked at
something and it appeared as something else for a time? For example spots in the wall
appearing as insects?" Formed visual and auditory hallucinations were assessed with the
following questions: "Have you had visions of people, animals, or objects that were in fact not
there?", "Did you hear these people/animals/objects make any noise?", "Have you heard
sounds of people talking, music, or other noises when in fact there was no sound?" We asked
the participants to answer the questions based on their experiences since they were diagnosed
with PD.
We also measured the patients' visual acuity and contrast sensitivity using the Freiburg Visual
Acuity and Contrast Test (FrACT version 3.5).366 The acuity test started with the presentation of
a large black Landot C on a white background that could be oriented up, down, left, or right.
Participants had to indicate the direction of the gap in the letter orally by saying "up", "down",
"left", or "right". Using the adaptive Best PEST algorithm, 3 67 FrACT changes the size of the
letter until it converges on the participant's acuity threshold, defined as the point of inflection
in a participant's psychometric curve. The orientation of the letters changed randomly from
trial to trial. A decimal acuity of 1.0 corresponds to Snellen acuity of 20/20. Contrast threshold,
evaluated as Michelson contrast, was measured in the same manner as the acuity test, except
that only the contrast between the original large Landot C and its background changed from
trial to trial. Participants completed 30 trials for the acuity test, and 30 trials for the contrast
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sensitivity test while seated comfortably at a distance of roughly 2.7 meters from the computer
screen in a dimly lit room. Due to testing time restrictions, we were able to collect acuity and
contrast sensitivity measures from a subset of patients in each group; hence these data are
available for 16, 17, and 22 patients in the control, benign, and formed subgroups, respectively.
5.2.4 Genotyping
Genotyping was carried out according to the protocol described in Chapter 2. In our sample,
27, 76, and 32 patients fell in the COMT Val/Val, Val/Met, and Met/Met groups, respectively.
The DRD2 C957T break down was 21 C/C, 70 C/T, and 44 T/T. These distributions did not
depart from the Hardy-Weinberg equilibrium (COMT: Y2 = 2.194, df = 1, p = 0.139; DRD2: x2
0.625, df = 1, p = 0.429).
5.2.5 Statistical analysis
We used a chi-square test, or Fisher's exact test (if any cell count was 5), to compare the
frequency of COMT and DRD2 alleles and genotypes among the control, benign, and formed
subgroups. Letter sizes in the acuity test followed a geometric progression; 368 thus, we applied
a log transform (IogMAR = -log[decimal acuity]) before comparing acuity between the
groups. 3 69 All data were analyzed using MATLAB 2009a (MathWorks Inc., Natick, MA) and SPSS
11.5 (SPSS Inc., Chicago, IL).
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5.3 Results
Among the 135 participants, 63 (46.7%) experienced benign hallucinations and 35 (25.9%)
experienced formed visual or auditory hallucinations (Table 5.2). Among patients with benign
hallucinations, passage hallucinations were the most prevalent (34.8%) type, followed by
illusions (23.7%), and presence (17.0%) hallucinations.
Among those with formed hallucinations, purely visual experiences were the most common
(17.0%). Only 4.4% experienced purely auditory hallucinations (Table 5.3). The majority
(91.4%) of those experiencing formed hallucinations experienced benign hallucinations as well
(Table 5.4), while 31.0% of patients without formed hallucinations experienced benign
hallucinations.
A comparison of the control and benign subgroups revealed that the controls had significantly
longer disease duration (control: mean disease duration = 8.3 yrs, SD = 2.7 yrs; benign: mean
disease duration = 5.6 yrs, SD = 4.6 yrs, p = 0.011 two-tailed) and took significantly larger
amounts of dopaminergic medications (control: mean LEDD = 891.6 mg, SD = 539.5 mg; benign:
mean LEDD = 557.3 mg, SD = 422.8 mg; p = 0.011 two-tailed) (Table 5.5). The age at onset for
the controls was significantly lower than that of the formed subgroup (control: age at onset
56.0, SD = 8.1; formed: age at onset 61.0, SD = 9.2; p = 0.030). The benign and control
subgroups, and the formed and control subgroups were not significantly different with respect
to sex, age, disease severity, number taking dopamine agonists, MMSE, BDI, years of education,
visual acuity, or contrast sensitivity threshold.
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The allele (Table 5.6) and genotype (Table 5.7) distributions for DRD2 and COMT did not differ
significantly between the benign and control subgroups. While the DRD2 allele (Table 5.8) and
genotype (Table 5.9) frequencies were similar between the formed and control subgroups, the
Met allele of COMT was under-represented and the Val allele was over-represented among the
formed subgroup relative to the controls (X2 = 4.649, df = 1, p = 0.031). The Val/Val genotype of
COMT occurred in 72.7% of the formed subgroup but only 27.3% of the controls, while the
Met/Met genotype was present in 68.8% of the controls but only 31.3% of the formed
subgroup (p = 0.043, Fisher's exact test).
5.4 Discussion
This experiment tested the hypothesis that increased dopamine signaling is associated with the
occurrence of hallucinations in PD. To answer this question, we divided a cohort of 135
patients into 3 subgroups: those with benign, but not formed, hallucinations (benign subgroup),
those with formed hallucinations (formed subgroup), majority of whom also experienced
benign hallucinations, and those without any hallucinations (control subgroup). To limit the
possibility of including patients who may develop hallucinations at a later date, the control
subgroup was limited to patients who had had PD for at least 5 years. Because of this inclusion
restriction, the controls had a significantly longer disease duration and took significantly larger
amounts of dopaminergic medications relative to the benign subgroup, and they had a
significantly younger age at onset relative to the formed subgroup.
Visual acuity and contrast sensitivity
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Visual acuity and contrast sensitivity thresholds were similar between the formed and control
subgroups in our cohort. Other laboratories reported that PD patients with hallucinations,
relative to those without hallucinations, had reduced visual acuity and contrast
sensitivity.30,3's,3 In one study, those with hallucinations had a significantly longer disease
duration relative to non hallucinators,308 while disease duration was similar for the two groups
in the other studies. 307,370 Because we limited our controls to those who had had the disease
for at least five years, our controls had a significantly younger disease onset and marginally
longer disease duration relative to the formed subgroup. Our negative finding, therefore, could
be due to the longer disease duration of the controls, because those with longer disease
durations probably had more dopamine loss in their retina than those with shorter disease
durations.
Impact of D2 variation on hallucinations
Makoff and colleagues (2000) found that the A2/A2 genotype of ANKK1 Taq1A polymorphism,
which results in increased D2 receptor density in the striatum, was disproportionately over-
represented in patients who developed hallucinations later in the disease. Kaiser et al. (2003)
and Wang et al. (2004), however, were not able to replicate these results.36 3,36 4 We did not find
an association between DRD2 C957T-which is in strong (d' = 0.832 to 1) linkage disequilibrium
with ANKK1 Taq1A 13 2,134-and benign or formed hallucinations. It is likely, therefore, that the
ANKK1 Taq1A and DRD2 C957T polymorphisms do not alter the risk for developing
hallucinations in PD.
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Another reason for the discrepant results may be due to the different methods used to
document hallucinations. Makoff et al. (2000) used a semi-structured interview and included
patients who experienced hallucinations (visual, auditory, tactile, olfactory, or gustatory)
anytime after starting dopamine replacement therapy. Wang et al. used Makoff's method, but
they included only those who experienced hallucinations for a minimum of three times a week
for at least 3 months. 36 3 Kaiser and colleagues included patients who had a score of grater than
1 on the UPDRS "Thought Disorder" questions, indicating a presence of hallucinations or
delusions.364 Goetz and colleagues (2001) also used an interview based method, but they
limited their study to those who had experienced visual hallucinations at least 3 times per week
for the two months prior to the interview. We used a validated self-report questionnaire365 to
document the presence of visual and auditory hallucinations that occurred anytime after
patients started taking dopamine replacement therapy. In summary, lack of a universal method
of defining groups with hallucinations complicates cross study comparisons.
Impact of COMT variation on hallucinations
We found that Val allele of COMT was disproportionately represented among the formed
subgroup, relative to the controls, and noticed a trend (p = 0.163) for overexpression of Val in
the benign subgroup. Animal studies have shown that activity of neurons in the PFC follows an
inverted-U curve in response to exogenous dopamine: low to moderate amounts of dopamine
"focus" the activity of neurons by sharpening their tuning curves, whereas excessive amounts
of dopamine silence the neurons.99~101 Functional MRI and PET imaging studies in PD patients
suggest that patients who experience hallucinations, relative to those who do not, have
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increased activity in the PFC.31s,371,372 The low-activity Met allele of COMT putatively results in
excessive amounts of dopamine in the frontal cortex,78 and through suppression of neuronal
activity,99-101 likely creates an unfavorable environment for induction and maintenance of
spontaneous aberrant cortical activities that would be misinterpreted as external stimuli.
Picking a PD control subgroup
No consensus exists on a method of selecting PD controls to discover genetic risk factors for
hallucinations. A critical issue was the possibility that PD patients in the control group may
start experiencing hallucinations after testing. Investigators have addressed this challenge in
different manners. Three studies included patients with a minimum disease duration of five
years in the control group to limit the possibility of including future hallucinators,363,33,34 and
another laboratory excluded patients with a disease duration of five years or less from the
control group. 102 Three studies, however, did not place disease duration restrictions on the PD
control set.3 62' 375 ,376 Because of this lack of consensus, we re-analyzed our data by removing
the disease duration restriction from our control subgroup. The new control and formed
subgroups had 69 and 35 participants, respectively. We found that the proportion of COMT
Val158Met and DRD2 C957T genotypes and alleles was similar between those with formed
hallucinations and PD controls (all p > 0.27) in the new analysis. This negative finding may be
due to the inclusion of future hallucinators in the control set, or may reflect a true lack of
association between COMT and DRD2 variation and hallucinations in PD.
To select an un-controversial control set, one must follow patients from the test date to death
to ensure that none develops hallucinations. Given that this approach is not feasible, we
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believe the next best choice is to limit the control group to those who have been taking
dopamine replacement therapy for several years without experiencing any hallucinations. This
group is likely more resistant to medication induced hallucinations and thus provides a rational
and conservative baseline for discovering genetic risk factors.
Conclusions
We showed that the Val allele of COMT was over-represented in PD patients who experienced
formed hallucinations while taking dopamine replacement therapy. When our results are
validated by other investigators, Val can serve as a biomarker for early identification of at risk
individuals. Careful monitoring of these patients will reduce the likelihood of undetected and
untreated hallucinations.
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Characteristics of PD patients who completed the Queen Square Visual
Hallucination Inventory
Variable
No. of participants
Age (yrs)
Age at PD onset
PD duration (yrs)
Stage 1
H&Y Stage 2
Stage 3
LEDD (mg/day)
No. taking agonists
MMSE
BDI
Education (yrs)
Results are presented as mean (SD),
PD patients
135 (87M; 48F)
66.6 (8.7)
61.0 (9.5)
5.6 (3.8)
17
108
10
614.9 (429.6)
76 (56.3%)
28.2 (1.3)
6.3 (4.2)
16.7 (2.9)
number, or percentage.
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Table 5.1
Frequency of formed and benign hallucinations
Hallucination
Benign
illusions
passage
presence
Formed
visual
auditory
No. of patients (%)
63 (46.7%)
32 (23.7%)
47 (34.8%)
23 (17.0%)
35 (25.9%)
29 (21.5%)
12 (8.9%)
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Table 5.2
Frequency of formed visual and auditory hallucinations
Auditory
No Yes Total
No 100 (74.1%) 6 (4.4%) 106 (78.5%)
Visual
Yes 23 (17.0%) 6 (4.4%) 29 (21.5%)
Total 123 (91.1%) 12 (8.9%) 135 (100%)
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Table 5.3
Overlap between formed and benign hallucinations
Benign
No Yes Total
No 69 (51.1%) 31 (23.0%) 100 (74.1%)
Formed
Yes 3 (2.2%) 32 (23.7%) 35 (25.9%)
Total 72 (53.3%) 63 (46.7%) 135 (100%)
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Table 5.4
Table 5.5 Characteristics of patients in control, benign, and formed subgroups
Variable
No. of participants
Sex M:F
Age (yrs)
Age at PD onset
PD duration (yrs)
Stage 1
H&Y Stage 2
Stage 3
LEDD (mg/day)
% taking agonists
Other medications
Control
subgroup
26
15:11
64.3 (8.3)
56.0 (8.1)
8.3 (2.7)
4
19
3
891.6 (539.5)
53.8%
Benign
subgroup
31
21:10
65.7 (8.6)
60.2 (10.8)
5.6 (4.6)
2
29
0
557.3 (422.8)
51.6%
% taking Namenda 0% 0%
% taking Exelon 0% 0%
% taking Aricept 0% 3.2%
% taking Artane 7.7% 6.5%
% taking Amantadine 15.4% 22.6%
% taking Bupropion 3.8% 0%
MMSE 28.1 (1.3) 28.4 (1.2)
BDI 5.9 (4.6) 7.2 (3.9)
Education (yrs) 16.5 (2.4) 16.8 (2.9)
Acuity (logMAR) 0.15 (0.18) 0.16 (0.19)
Contrast sensitivity 5.32 (3.39) 3.89 (2.29)
§ t test; X Chi square test; E Fisher's exact test; ANOVA with age
Results are presented as mean (SD), number, or percentage.
Significant results are indicated in bold font.
p Value
Control vs.
benign
p Value
Control vs.
formed
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Formed
subgroup
35
24:11
67.8 (9.4)
61.0 (9.2)
6.8 (4.0)
3
27
5
692.8 (422.4)
68.6%
2.9%
5.7%
2.9%
11.4%
28.6%
0%
27.8 (1.3)
6.7 (5.2)
16.5 (3.3)
0.24 (0.20)
5.84 (4.07)
as covariate.
0.433
0.514 §
0.111 §
0.011 §
0.069 E
0.011 §
0.866
0.479 §
0.252 §
0.745 §
0.842*
0.163*
0.382Y
0.130 §
0.030 §
0.113 §
0.691E
0.112 §
0.241 *
0.354 §
0.522 §
0.975 §
0.154*
0.678*
Table 5.6 Allele frequencies of DRD2 C957T and COMT Val158Met polymorphisms in
control and benign subgroups
Polymorphism Alleles Control subgroup Benign subgroup p Value
DRD2 C957T C 24 (52.2%) 22 (47.8%) 0.693y
T 28 (48.3%) 30 (51.7%)
COMT Val158Met V 18 (41.9%) 25 (58.1%) 0.163 y
M 34 (55.7%) 27 (44.3%)
Y Chi square test.
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Table 5.7 Genotype frequencies of DRD2 C957T and COMTVal158Met polymorphisms in
control and benign subgroups
Polymorphism Genotype Control subgroup Benign subgroup p Value
C/C 5 (55.6%) 4 (44.4%)
DRD2 C957T C/T 14 (50.0%) 14 (50.0%) 0.484 E
T/T 7 (35.0%) 13 (65.0%)
V/V 3 (42.9%) 4 (57.1%)
COMTVal158Met V/M 12 (41.4%) 17 (58.6%) 0.809 E
M/M 11 (52.4%) 10 (47.6%)
E Fisher's exact test.
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Table 5.8 Allele frequencies of DRD2 C957T and COMT Val158Met polymorphisms in
control and formed subgroups
Polymorphism Allele Control subgroup Formed subgroup p Value
DRD2 C957T C 24 (41.4%) 34 (58.6%) 0.791y
T 28 (43.8%) 36 (56.3%)
COMT Val158Met V 18 (32.1%) 38 (67.9%) 0.031y
M 34 (51.5%) 32 (48.5%)
Y Chi square test.
Significant results are in bold font.
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Table 5.9 Genotype frequencies of DRD2 C957T and COMT Val158Met polymorphisms in
control and formed subgroups
Polymorphism Genotype Control subgroup Formed subgroup p Value
C/C 5 (41.7%) 7 (58.3%)
DRD2 C957T C/T 14 (41.2%) 20 (58.8%) 0.940 E
T/T 7 (46.7%) 8 (53.3%)
V/V 3 (27.3%) 8 (72.7%)
COMTVal158Met V/M 12 (35.3%) 22 (64.7%) 0.043 E
M/M 11 (68.8%) 5 (31.3%)
E Fisher's exact test.
Significant results are in bold font.
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6 Conclusions
In four experiments, we tested the hypothesis that pharmacogenetic elevation of dopamine
signaling in the brain regions that are relatively spared from dopamine loss in the early stages
of PD would result in cognitive dysfunction. In particular, we predicted that specific alleles of
COMTVaI158Met, DRD2 C957T, DRD3 Ser9Gly, and DRD4 exon Ill 48bp VNTR polymorphisms
that putatively enhance dopamine signaling would cause impulse control behaviors and
hallucinations in PD patients taking dopamine replacement therapy.
Our hypothesis stemmed from the inverted-U dopamine response curve, whereby too little or
too much dopamine results in cognitive dysfunction.92 ,93 Brain networks that are implicated in
the occurrence of hallucinations and impulsive behaviors are primarily interconnected with the
VTA, which is relatively spared from dopamine loss in the early stages of PD. 24 We reasoned
that exogenous dopamine would overdose these networks in patients who carried specific
polymorphisms that increase dopamine signaling, and thus, would result in psychiatric side
effects.
We addressed five specific questions: (1) Are COMT Met/Met and Val/Met carriers more
impulsive than Val/Val carriers?, (2) Are DRD2 T/T and C/T carriers more impulsive than C/C
carriers?, (3) Are DRD3 Gly/Gly carriers more impulsive than Ser/Gly and Ser/Ser carriers?, (4)
Are D4.7- carriers more impulsive than D4.7+ carriers?, (5) Are Met allele of COMT, T allele of
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DRD2, Gly allele of DRD3, and absence of the 7-repeat allele of DRD4 associated with
hallucinations? We predicated that individuals with the variants of COMT (Met allele), DRD2 (T
allele), DRD3 (Gly allele), and DRD4 (absence of 7-repeat allele) that increase dopamine
signaling would show behavioral impulsivity and would experience hallucinations due to
dopamine overdose.
Consistent with our hypothesis, we found that carriers of the COMT Val/Met and Met/Met
genotypes were more impulsive than Val/Val carriers on the Stop Signal Task (Chapter 2).
Individuals with the T/T genotype of DRD2 showed reduced ability to delay gratification
compared to C/T and C/C carriers (Chapter 3). Patients with the DRD2 T/T genotype showed
more reflection impulsivity than C/C carriers. We also uncovered an interaction between COMT
and DRD2 whereby those individuals who had the genotype combination that is associated with
high baseline dopamine levels were reflection impulsive (Chapter 4). Contrary to our
hypothesis, we found that the Val allele of COMT was associated with hallucinations (Chapter
5). We could not study DRD3 and DRD4 due to the small number of Gly and D47+ carriers.
Our results suggest that pharmacogenetic elevation of dopamine signaling results in increased
impulsivity, and thus maybe cause impulse control behaviors-binge eating, excessive
shopping, pathological gambling, and hypersexuality-in patients who are taking dopamine
replacement therapy. This finding provides a springboard for future work that will directly
examine whether medication-induced impulse control behaviors in PD are linked with
polymorphisms in COMT and DRD2. We only examined one single nucleotide polymorphism on
each gene. Future studies should examine multiple polymorphisms on each gene to assess
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whether the combination of these polymorphisms provides increased predictive power. They
should also attempt to measure dopamine levels-perhaps by examination of prolactin levels-
to provide needed empirical support for gene-dopamine interactions.
Over-representation of the COMTVal-and under-representation of the COMT Met-allele in
individuals with hallucinations provides an immediate biomarker for early identification of at
risk individuals. Hallucinations are a side effect of dopamine replacement therapy and are
linked with hyperactivity in the PFC. 4 3,44,303 Pharmacological experiments in animals showed
that too much dopamine in the PFC resulted in a general silencing of neuronal firing.99~101 We
posit that excessive PFC dopamine levels, due to exogenous dopamine and the presence of the
COMT Met isoform, would not allow the occurrence of self-organized spontaneous neuronal
activations that would be misinterpreted as external stimuli, i.e., a hallucination.
Because hallucinations in PD are predominantly friendly or non-threatening, many patients do
not report them to their neurologists. If not treated early, however, hallucinations persist and
progress and are a significant risk factor for dementia, nursing home placement (and thus
increased mortality rates).46-50 An objective hallucination risk biomarker will allow neurologists
to carefully monitor treatment levels for these patients to reduce the risk of hallucinations and
institutionalization.
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